Document:

EX-10.15

 Exhibit 10.15 

LICENSE AGREEMENT 

between 
 MEDIMMUNE, LLC

 and 
 VIELA
BIO, INC. 
 Dated as of February 23, 2018 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 TABLE OF CONTENTS 

 

									
	 	 	 	  	 	  	Page	 
		
	 ARTICLE 1 DEFINITIONS
	  	 	1	 
				
		 	 1.1.
	  	Definitions in this Agreement	  	 	1	 
		
	 ARTICLE 2 GRANT OF RIGHTS
	  	 	3	 
				
		 	 2.1.
	  	License Grant	  	 	3	 
		 	 2.2.
	  	Sublicensing	  	 	3	 
		 	 2.3.
	  	Access right	  	 	3	 
		 	 2.4.
	  	MedImmune R&D Tools	  	 	3	 
		 	 2.5.
	  	Excluded Manufacturing Know-How	  	 	4	 
		 	 2.6.
	  	No Other Rights Granted by MedImmune	  	 	4	 
		
	 ARTICLE 3 CONFIDENTIALITY AND
NON-DISCLOSURE
	  	 	4	 
				
		 	 3.1.
	  	Confidentiality	  	 	4	 
		 	 3.2.
	  	Licensed Know-How	  	 	4	 
		 	 3.3.
	  	Publications	  	 	4	 
		
	 ARTICLE 4 INTELLECTUAL PROPERTY
	  	 	5	 
				
		 	 4.1.
	  	Prosecution of the 4920 Patents	  	 	5	 
		 	 4.2.
	  	Enforcement of 4920 Patents	  	 	5	 
		
	 ARTICLE 5 INDEMNITY, LIMITATIONS AND INSURANCE
	  	 	6	 
				
		 	 5.1.
	  	Indemnification	  	 	6	 
		 	 5.2.
	  	Limitation of Liability	  	 	6	 
		 	 5.3.
	  	Disclaimer of Warranties	  	 	6	 
		 	 5.4.
	  	Insurance	  	 	7	 
		
	 ARTICLE 6 TERM AND TERMINATION
	  	 	7	 
				
		 	 6.1.
	  	Term and Expiration	  	 	7	 
		 	 6.2.
	  	Termination	  	 	7	 
		 	 6.3.
	  	Effects of Termination	  	 	8	 
		 	 6.4.
	  	Accrued Rights; Surviving Obligations	  	 	8	 
		 	 6.5.
	  	Bankruptcy	  	 	8	 
		
	 ARTICLE 7 MISCELLANEOUS
	  	 	9	 
				
		 	 7.1.
	  	Independent Contractor	  	 	9	 
		 	 7.2.
	  	Governing Law, Jurisdiction, Venue and Service	  	 	9	 
		 	 7.3.
	  	Service	  	 	9	 
		 	 7.4.
	  	Notices	  	 	9	 
		 	 7.5.
	  	No Benefit to Third Parties	  	 	10	 
		 	 7.6.
	  	Waiver and Non-Exclusion of Remedies	  	 	11	 
		 	 7.7.
	  	Assignment	  	 	11	 

  
 i 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 TABLE OF CONTENTS 

(continued) 
  

									
	 	 	 	  	 	  	Page	 
				
		 	 7.8.
	  	 Amendment
	  	 	12	 
		 	 7.9.
	  	 Severability
	  	 	12	 
		 	 7.10.
	  	 English Language
	  	 	12	 
		 	 7.11.
	  	 Counterparts
	  	 	12	 
		 	 7.12.
	  	 Entire Agreement
	  	 	12	 
		 	 7.13.
	  	 Construction
	  	 	13	 

  
 ii 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 LICENSE AGREEMENT 

This License Agreement (this “Agreement”) is made and entered into as of February 23, 2018 (the
“Effective Date”) by and between MedImmune, LLC, a Delaware corporation (and a member of the AstraZeneca group of companies) (“MedImmune”) and Viela Bio, Inc., a Delaware corporation (“Spinco”).
MedImmune and Spinco are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 

Recitals 
 WHEREAS,
MedImmune, MedImmune Limited and AstraZeneca Collaboration Ventures, LLC has agreed to sell, or to procure the sale, to Spinco, of certain assets relating to certain products and programs aimed at treating inflammation and autoimmune disorders,
including specified Patents and Know-How relating exclusively to such products or programs, on the terms and subject to the conditions set forth in that certain Asset Purchase Agreement dated February 23,
2018 (the “APA”); 
 WHEREAS, MedImmune or its applicable Affiliate is willing to license certain other Patents and Know-How of MedImmune or its applicable Affiliate relating (but not exclusively) to the Products (each as defined in the APA) and Spinco is willing to receive such license on the terms of this Agreement; 

NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

ARTICLE 1 
 DEFINITIONS

 1.1.    Definitions in this Agreement. Unless otherwise specifically provided herein, capitalized words
and phrases used in this Agreement shall have the meaning ascribed to them in the APA. In addition, the following terms shall have the following meanings: 

“4920 Patents” means the Patents listed in Schedule 1. 

“Agreement” has the meaning set forth in the preamble hereto. 

“Assignment” has the meaning set forth in Section 7.7.2. 

“APA” has the meaning set forth in the Recitals. 

“Effective Date” has the meaning set forth in the preamble hereto. 

“Field” means all human uses and indications including the treatment, palliation, diagnosis, cure or prevention of any human
disease, disorder or condition. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 “Exploit” means to develop, make, have made, use, manufacture, have
manufactured, market, import, export, offer for sale and sell and “Exploiting” and “Exploitation” shall have corresponding meanings. 

“Licensed Intellectual Property” means, with respect to the Products and Programs, any Patents and Know-How that (a) are owned or controlled by MedImmune or its Affiliates as at the Effective Date and (b) were used by MedImmune or its Affiliates in the Development of such Product, are specific to any of
the Programs or Products prior to the Effective Date, or are necessary for the Exploitation of the Product or Programs by Spinco after the Effective Date, but excluding any and all (i) Assigned Intellectual Property, (ii) Excluded
Manufacturing Know-How; and (iii) any Patents, Know-How or other intellectual property rights subject to the Assigned Contracts, the AMG Collaboration Agreement or
the In-License Agreements. 
 “Licensed
Know-How” means Know-How that is Licensed Intellectual Property. 
 “Major Market
Country” means the United States, the United Kingdom, France, Germany, Italy, Spain and Japan. 
 “MedImmune” has
the meaning set forth in the preamble hereto. 
 “MedImmune Internal R&D Tools” means biological materials,
assays and other research and development tools that (a) are owned or controlled by MedImmune or its Affiliates as at the Effective Date, (b) were used by MedImmune to Develop a Product prior to the Effective Date and (c) may be
useful for the continued Development of such Product. For clarity, (i) the biological materials listed in Schedule 2 are MedImmune Internal R&D Tools. 

“MedImmune Shared R&D Tools” means biological materials, assays and other research and development tools that
(a) are owned or controlled by MedImmune or its Affiliates as at the Effective Date, (b) were used by MedImmune to Develop a Product prior to the Effective Date and (c) are necessary for the continued Development of such Product. For
clarity, (i) the biological materials listed in Schedule 3 are MedImmune Shared R&D Tools and (ii) the biological materials listed in Schedule 2 are not MedImmune Shared R&D Tools. 

“Notice” has the meaning set forth in Section 7.4.1. 

“Party” and “Parties” have the meanings set forth in the preamble hereto. 

“Publication” has the meaning set forth in Section 3.3. 

“Spinco” has the meaning set forth in the preamble hereto. 

  
 2 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 ARTICLE 2 

GRANT OF RIGHTS 

2.1.    License Grant. Subject to the terms of this Agreement and the Transaction Agreements, MedImmune hereby
grants to Spinco, with effect from the Effective Date, on a Product-by-Product basis, a perpetual and irrevocable (subject to Sections 6.2 and 6.3), sub-licensable (subject to Section 2.2) exclusive (to the extent that MedImmune or its Affiliate has exclusive rights, provided that the license with respect to research shall be
non-exclusive), worldwide, royalty-free license under the Licensed Intellectual Property solely for the purpose of Exploiting such Product in the Field; provided that with respect to Products that are Licensed
Products (as defined in the [***] [***] Term Sheet or, on execution, the [***] Agreement), the Field shall exclude the Kidney Field (as defined in the [***] Term Sheet or, on execution, the [***] Agreement). Notwithstanding the grant of the license
in this Section 2.1 nothing shall prevent MedImmune or any of its Affiliates from carrying out its and/or its Affiliate’s obligations or exercising its right under or pursuant to this Agreement, any Transaction Agreement or the [***]
Agreement or from Developing, commercializing or otherwise exploiting (i) anifrolumab in any disease area or (ii) any medicinal product (other than with respect to Products as expressly transferred under the APA) for the treatment,
prevention or diagnosis of any diseases in the therapeutic areas of oncological, asthma, chronic obstructive pulmonary disease, diabetes, cardiovascular, idiopathic pulmonary fibrosis, chronic kidney disease and chronic kidney failure. 

2.2.    Sublicensing. Spinco may grant sublicenses (and authorize the granting of sublicenses), through multiple
tiers, under the license granted in Section 2.1 to Affiliates and Third Parties in connection with a license to Exploit the applicable Product; provided that Spinco shall require any such sublicensee to comply with the terms and conditions of
this Agreement that are applicable to sublicensees and shall be liable for all and any acts and omissions of any such sub-licensee in connection with such sublicense, including in respect of any Third Party
claim made against MedImmune or any of its Affiliates resulting from such acts or omissions. 
 2.3.    Access
right. To the extent that Licensed Know-How is contained in Regulatory Materials and Documents that relate to the Products and Programs that are not included in the Acquired Assets and copies of such
Licensed Know-How have not otherwise been made available to Spinco pursuant to the APA, MedImmune shall, upon Spinco’s request and in conjunction with the services provided pursuant to the Transition
Services Agreement, promptly provide to Spinco electronic copies of such Licensed Know-How. 

2.4.    MedImmune R&D Tools. During the period of [***] following the Effective Date, the Parties shall
cooperate to identify the MedImmune Shared R&D Tools (to the extent not included on Schedule 3), and MedImmune shall provide Spinco with samples of such tools. The MedImmune Shared R&D Tools and any materials derived from such tools shall be
deemed to be the Confidential Information of MedImmune. Spinco shall only use the MedImmune Shared R&D Tools for the purpose of Development of the applicable Product and shall only disclose and transfer them to Spinco’s sublicensees for the
relevant Product to the extent useful or necessary for such sublicensee to Develop such Product in accordance with the terms of its sublicense; provided that such sublicensee is subject to obligations of
non-disclosure and non-use at least as protective of the MedImmune Shared R&D Tools as those set out in this Agreement. Spinco shall have no direct access to the
MedImmune Internal R&D Tools but MedImmune may use such tools in connection with the provision of services under the Development Services Agreement. 

  
 3 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 2.5.    Excluded Manufacturing
Know-How. For clarity, the license in Section 2.1 does not include any right or license for Spinco to access or use Excluded Manufacturing Know-How and
Spinco’s rights and obligations with respect to Excluded Manufacturing Know-How shall be subject to the Clinical Supply Agreement and the Development Services Agreement. 

2.6.    No Other Rights Granted by MedImmune. Except as expressly provided herein and without limiting the
foregoing, MedImmune grants no other right or license to Spinco. 
 ARTICLE 3 

CONFIDENTIALITY AND NON-DISCLOSURE 

3.1.    Confidentiality. Section 7.2 of the APA is hereby incorporated by reference into this Agreement,
mutatis mutandis. 
 3.2.    Licensed Know-How. The Licensed Know-How shall at all times remain the Confidential Information of MedImmune and shall only be used by Spinco as permitted for Spinco to exercise its rights and fulfill its obligations under this Agreement. Spinco,
its Affiliates and sublicensees may only disclose the Licensed Know-How (a) to Regulatory Authorities to the extent necessary to obtain any Regulatory Approval for such Product provided that reasonable
measures shall be taken to assure confidential treatment of such Confidential Information, (b) to sublicensees of the relevant Product to the extent useful or necessary for such sublicensee to Exploit the Product in accordance with the terms of
its sublicense provided that such sublicensee is subject to obligations of non-disclosure and non-use at least as protective of the Licensed Know-How as those set out in this Agreement or (c) in Publications provided that Spinco has complied in full with the review procedures set forth in Section 3.3. 

3.3.    Publications. Spinco acknowledges and agrees that it shall not disclose in any publication (including
abstracts and manuscripts), public presentation or summaries of such publications or presentations any (a) Licensed Know-How or (b) any Know-How that is
Assigned Intellectual Property where the authors of such publication or presentation (or the Know-How contained therein) as determined according to the International Committee of Medical Journal Editors’
criteria for authorship are at the time of the proposed publication employees of MedImmune (“Relevant Know-How”), in each case (a) and (b) unless Spinco has complied in full with the
provisions of this Section 3.3. Spinco shall provide MedImmune with a copy of any proposed publication (including abstracts and manuscripts), public presentation or summary of such publication or presentation (each, a
“Publication”) (as applicable) that discloses any Licensed Know-How or Relevant Know-How, at least [***] prior to Spinco’s submission of such
Publication to a Third Party. MedImmune shall use reasonable endeavors to respond promptly to Spinco and shall in any event respond to Spinco within [***] after receipt of any proposed Publication as to whether: (a) MedImmune approves the
submission of such Publication, (b) MedImmune wishes to remove any Confidential Information of MedImmune from such Publication or (c) MedImmune wishes to delay such Publication for a period of up to [***] to permit filings for patent
protection and to otherwise address issues of Confidential Information or related competitive harm to the reasonable satisfaction of MedImmune. MedImmune may include in such notification any other reasonable comments with respect to such proposed
Publication. If MedImmune has not provided such notification to Spinco within 

  
 4 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
such [***] [***] period, Spinco shall be permitted to submit the proposed Publication in question. Spinco shall remove any Confidential Information of MedImmune notified to Spinco under clause
(b) prior to submitting such Publication and shall delay such Publication for any period notified by MedImmune to Spinco under clause (c). In addition, Spinco shall in good faith take into account any such other reasonable comments notified by
MedImmune. 
 ARTICLE 4 

INTELLECTUAL PROPERTY 

4.1.    Prosecution of the 4920 Patents. MedImmune shall have the right, but not the obligation, through counsel of
its choice, to prepare, file, prosecute and maintain the 4920 Patents, including directing any related interference, re-issuance, re-examination and opposition
proceedings with respect thereto. MedImmune shall (a) consult with Spinco as to the strategy for the prosecution of such preparation, filing, prosecution and maintenance, (b) solicit Spinco’s comments prior to any filing and consider
in good faith any comments from Spinco with respect thereto, and (c) keep Spinco reasonably informed of any material steps taken, and at Spinco’s request and cost provide copies of all material documents or correspondence filed, in
connection therewith in each Major Market Country. If MedImmune decides not to prepare, file, prosecute or maintain a 4920 Patent in a Major Market Country, MedImmune shall provide Spinco with written notice of such decision at least ninety
(90) days prior to any applicable filing deadline and, Spinco shall thereupon have the right, but not the obligation in its sole discretion, to assume the control and direction of the preparation, filing, prosecution and maintenance of such
4920 Patent at Spinco’s sole cost and expense in such country. 
 4.2.    Enforcement of 4920 Patents. Each
Party shall promptly report to the other Party any known or suspected infringement or unauthorized use of any 4920 Patent of which it becomes aware (the date of receipt of such notice by such other Party, the “Notice Date”) and
shall provide the other Party with all evidence within its possession or control supporting such known or suspected infringement or unauthorized use. MedImmune shall have the first right, but not the obligation, to prosecute any infringement with
respect to the 4920 Patents, including as a defense or counterclaim in connection with any action, at MedImmune’s sole cost and expense, using counsel of MedImmune’s choice. If MedImmune (i) notifies Spinco of its decision not to
enforce a 4920 Patent within ninety (90) days of the Notice Date or (ii) fails to take action to enforce a 4920 Patent within ninety (90) days of the Notice Date, in each case of (i) or (ii) Spinco shall thereupon have the right,
in its sole discretion, to assume the control and direction of the enforcement of such 4920 Patent the cost and expense in such country of which shall be borne solely by Spinco. If a Party is authorized to bring an enforcement action under this
Section 4.2, but the Party is not recognized by the applicable court or other relevant body as having the requisite standing to pursue such action, then the other Party shall, at the enforcing Party’s request and expense, join as a
party-plaintiff. Nothing in this Section 4.2 will be construed to limit Spinco’s rights to grant any sublicenses pursuant to Section 2.2. 

  
 5 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 ARTICLE 5 

INDEMNITY, LIMITATIONS AND INSURANCE 

5.1.    Indemnification. 

5.1.1.    Indemnification of MedImmune. Spinco shall reimburse, defend, indemnify and hold each AZ
Indemnified Party harmless from and against any and all Losses arising from Third Party claims incurred, resulting or arising from (a) any breach of or failure to perform any covenant or agreement made by Spinco in this Agreement;
(b) Exploitation of any Product by Spinco, its Affiliates or sublicensees; or (c) the gross negligence or willful misconduct of Spinco, its Affiliates or sublicensees, except in each case to the extent such Losses are subject to
indemnification pursuant to Section 5.1.2(a)-(b) below. 
 5.1.2.    Indemnification of
Spinco. MedImmune shall reimburse, defend, indemnify and hold each Spinco Indemnified Party harmless from and against any and all Losses arising from Third Party claims incurred, resulting or arising from (a) any breach of or failure
to perform any covenant or agreement made by MedImmune in this Agreement; or (b) the gross negligence or willful misconduct of MedImmune, its Affiliates, or licensees, except in each case to the extent such Losses are subject to indemnification
pursuant to Section 5.1.1 (a)-(c) above. 
 5.1.3.    Procedure. All indemnification claims made
pursuant to this Section 5.1 shall be subject to the indemnification procedures set forth in Section 9.4 of the APA, mutatis mutandis. 

5.2.    Limitation of Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS AGREEMENT, TO THE
FULLEST EXTENT PERMITTED BY APPLICABLE LAW AND EXCEPT AS A RESULT OF COMMON LAW FRAUD IN CONNECTION WITH MATTERS COVERED HEREIN OR A PARTY’S BREACH OF ITS CONFIDENTIALITY OBLIGATIONS HEREUNDER, AND EXCEPT WITH RESPECT TO ANY LIABILITY PURSUANT
TO SECTION 5.1, NEITHER SPINCO NOR MEDIMMUNE SHALL BE LIABLE TO THE OTHER OR THEIR AFFILIATES, FOR ANY CLAIMS, DEMANDS OR SUITS FOR CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE, INDIRECT OR MULTIPLE DAMAGES, FOR LOSS OF PROFITS, REVENUE
OR INCOME, DIMINUTION IN VALUE OR LOSS OF BUSINESS OPPORTUNITY (IN EACH CASE, WHETHER OR NOT FORESEEABLE AT THE EFFECTIVE DATE), OR FOR ANY DAMAGES CALCULATED BY REFERENCE TO A MULTIPLIER OF REVENUE, PROFITS, EBITDA OR SIMILAR METHODOLOGY, CONNECTED
WITH OR RESULTING FROM ANY BREACH OF THIS AGREEMENT, OR ANY ACTIONS UNDERTAKEN IN CONNECTION WITH, OR RELATED HERETO, INCLUDING ANY SUCH DAMAGES WHICH ARE BASED UPON BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE AND MISREPRESENTATION), BREACH OF
WARRANTY, STRICT LIABILITY, STATUTE, OPERATION OF LAW OR ANY OTHER THEORY OF RECOVERY. 
 5.3.    Disclaimer of
Warranties. EXCEPT AS EXPRESSLY SET FORTH IN ANY TRANSACTION AGREEMENT, MEDIMMUNE EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, WITH RESPECT TO THE LICENSED INTELLECTUAL PROPERTY OR
THIS AGREEMENT, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, OR NON-INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS. 

  
 6 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 5.4.    Insurance. During the term of this Agreement and for a
period of[***] [***] afterwards Spinco shall have and maintain such types and amounts of insurance covering its Exploitation of each Product as (i) is normal and customary in the pharmaceutical industry generally for parties similarly
situated; (ii) would normally be insured against by a prudent businessman in connection with the risks associated with this Agreement; and (iii) is otherwise required by Applicable Law. Upon request by MedImmune, Spinco shall provide to
MedImmune evidence of its insurance coverage. 
 ARTICLE 6 

TERM AND TERMINATION 

6.1.    Term and Expiration. This Agreement shall commence on the Effective Date and, unless earlier terminated in
accordance with Section 6.2, shall continue until the expiration, revocation, invalidation or abandonment of the last patent or patent application within the Licensed Patents, at which time the license granted to Spinco pursuant to
Section 2.1 shall become nonexclusive and irrevocable. 
 6.2.    Termination. 

6.2.1.    Termination for Breach. Either Party may terminate this Agreement immediately upon written notice
if the other Party, its Affiliates or sublicensees materially breaches any term or condition of this Agreement and fail to remedy such breach within [***] after being given written notice thereof; provided that if such breach relates to one or more
but not all Products, such termination shall be limited to the affected Product or Products. Notwithstanding the foregoing, if a Party disputes in good faith a breach alleged by the other Party pursuant to this Section 6.2.1 by written notice
to such other Party within such [***] period, such other Party shall not have the right to terminate this Agreement unless it has been determined pursuant to Section 7.2 that this Agreement was materially breached, and such Party fails to
comply with its obligations alleged to have been breached within [***] after such determination. 

6.2.2.    Termination on Insolvency. Either Party may terminate this Agreement immediately upon written
notice if the other Party (a) voluntarily declares or seeks protection under bankruptcy or insolvency laws, (b) has an involuntary petition in bankruptcy filed against it, which petition is not dismissed within [***] following it filing,
(c) has its business placed in the hands of a receiver or trustee and the appointment of such receiver or trustee if not dissolved within [***], or if (d) ceases to exist as an active business. 

6.2.3.    Termination for Patent Challenge. MedImmune may immediately terminate this Agreement with respect
to any Patent within the Licensed Intellectual Property immediately upon written notice to Spinco if Spinco or its Affiliates or, subject to the last two sentences of this Section 6.2.3, its sublicensees knowingly, directly or indirectly,
opposes or assists any Third Party in opposing the grant of such Patent, or disputes or knowingly, directly or indirectly, assists any Third Party in disputing, the validity or enforceability of such Patent or any of the claims thereof (each, a
“Patent Challenge”); [***] 

  
 7 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
[***] 
 6.2.4.    Spinco Termination Right.
Spinco may terminate this Agreement in its entirety or with respect to any particular Product for any reason upon sixty (60) days prior written notice to MedImmune. 

6.3.    Effects of Termination. 

6.3.1.    On termination of this Agreement by MedImmune under Section 6.2.1 (breach by Spinco),
Section 6.2.2 (insolvency of Spinco) or Section 6.2.3 (patent challenge) or by Spinco under Section 6.2.4 (termination at will), Spinco shall cease using the applicable Licensed Intellectual Property and
the rights and licenses granted under Article 2 shall terminate. 
 6.3.2.    Upon termination of this Agreement
by Spinco under Section 6.2.1 (breach by MedImmune) or Section 6.2.2 (insolvency of MedImmune), the licenses granted to Spinco in Article 2 shall survive such expiration or termination. 

6.4.    Accrued Rights; Surviving Obligations. Termination or expiration of this Agreement for any reason shall be
without prejudice to any rights that shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly or by implication intended to
come into or continue in force on termination or expiry of this Agreement, and [***] shall remain in full force and effect. 

6.5.    Bankruptcy. All rights and licenses granted under or pursuant to this Agreement from MedImmune to
Spinco are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code or any non-U.S. equivalent thereof, licenses of right to “intellectual property” as
defined under Section 101 of the U.S. Bankruptcy Code. MedImmune agrees that Spinco, as exclusive licensee of certain rights and licenses under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S.
Bankruptcy Code or any non-U.S. equivalent thereof (“Bankruptcy Laws”). MedImmune further agrees that, in the event of the commencement of a bankruptcy proceeding by or against MedImmune under
the Bankruptcy Laws, Spinco shall have the right to retain any and all rights and licenses granted to it hereunder, to the maximum extent permitted by such Bankruptcy Laws (such as under Sections 365(n)(1) and 365(n)(2) of the U.S. Bankruptcy Code
or any non-U.S. equivalent thereof) and be entitled to retain a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property
unless MedImmune (or its bankruptcy trustee) elects to assume this Agreement and continue to perform all of its obligations under this Agreement. 

  
 8 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 ARTICLE 7 

MISCELLANEOUS 

7.1.    Independent Contractor. The Parties and each of their respective Affiliates shall each be an independent
contractor in the performance of its obligations hereunder. 
 7.2.    Governing Law, Jurisdiction, Venue and
Service. 
 7.2.1.    Governing Law. This Agreement shall be governed by and construed in accordance
with the Laws of the State of New York, excluding any conflicts or choice of Law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive Law of another jurisdiction. 

7.2.2.    Jurisdiction. The Parties hereby irrevocably and unconditionally consent to the exclusive
jurisdiction of the courts of the State of New York and the United States District Court for the Southern District of New York for any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and agree
not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties irrevocably and unconditionally waive their right to a jury trial in connection with any litigation arising out of or
relating to this Agreement or the transactions contemplated hereby. 
 7.2.3.    Venue. The Parties
further hereby irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of the State of New York or in the
United States District Court for the Southern District of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has
been brought in an inconvenient forum. 
 7.3.    Service. Each Party further agrees that service of any process,
summons, notice or document by registered mail to its address set forth in Section 7.4.2 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court. 

7.4.    Notices. 

7.4.1.    Notice Requirements. All notices or other communications which are required or permitted hereunder
(each, a “Notice”) shall be in writing and sufficient if delivered personally or sent by nationally recognized overnight courier or by registered or certified mail, postage prepaid, return receipt requested, or by facsimile or
email, addressed to the Parties at their respective addresses specified in Section 7.4.2 or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance

  
 9 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
herewith. All such notices and other communications required or permitted by this Agreement shall be deemed to have been duly given (a) if sent to a recipient at the proper address as
determined pursuant to this Section 7.4.1 by registered or certified mail, return receipt requested, five calendar days after being deposited in the United States mail, postage prepaid; (b) if sent by Express Mail, Federal Express or
similar reputable overnight delivery service that maintains records of receipt for next Business Day delivery, the next Business Day after being entrusted to such service, with delivery charges prepaid or charged to the sender’s account;
(c) if sent by facsimile transmission or email, on the date of transmission with electronic confirmation of transmission; and (d) if delivered by hand, on the date of delivery. 

 

			
	7.4.2.	  	Address for Notice.
		
		  	If to MedImmune, to:
		
		  	MedImmune, LLC
		  	950 Wind River Lane
		  	Gaithersburg, MD 20878
		  	Attention: General Counsel
		
		  	With a copy (which shall not constitute notice) to:
		
		  	 [***]

		  	 [***]

		  	 [***]

		  	 [***]

		  	 [***]

		
		  	If to Spinco, to:
		
		  	Viela Bio, Inc.
		  	1 Medimmune Way
		  	Gaithersburg, MD 20878
		  	Attention: Bing Yao
		
		  	With a copy (which shall not constitute notice) to:
		
		  	Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
		  	701 Pennsylvania Ave., NW, Suite 900
		  	Washington, DC 20004
		  	Attention: Christopher Jeffers

 7.5.    No Benefit to Third Parties. The covenants and agreements set forth in this
Agreement are for the sole benefit of the Parties and their successors and permitted assigns, and, except for the rights of any indemnified Person under Article 5, they shall not be construed as conferring any rights on any other Persons. 

  
 10 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 7.6.    Waiver and
Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in
a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any
other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by applicable Law or
otherwise available except as expressly set forth herein. 
 7.7.    Assignment. 

7.7.1.    No Party may assign or transfer this Agreement or any rights or obligations hereunder, directly or
indirectly (by operation of Law or otherwise), without the prior written approval of the other Party and any attempted assignment without such required approval shall be null, void and of no effect; provided, however, that (a) MedImmune may
assign its rights, interests or obligations hereunder to an Affiliate of MedImmune or to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or substantially all of the business to which this Agreement
relates , in each case without Spinco’s prior written approval and (b) Spinco may assign its rights, interests, and obligations hereunder (in whole and not in part) to a wholly owned Affiliate of Spinco without MedImmune’s prior
written approval. In addition, following the earlier to occur of (c) the consummation in full of the Milestone Closing (as defined in the Securities Purchase Agreement) and (d) the consummation of a Qualified IPO (as defined in the
Restated Certificate (as defined in the Securities Purchase Agreement)), Spinco may assign its applicable rights, interests, and obligations hereunder related to one or more Programs to a Third Party without MedImmune’s prior written approval,
so long as (i) such assignment shall be in connection with the divestment by Spinco of all or substantially all of the assets relating to such Program or Programs (whether by asset purchase or exclusive
out-license), (ii) in connection therewith, Spinco also assigns to such Third Party its applicable rights, interests, and obligations under the other Transaction Agreements related to such Program or Programs,
and (iii) proper provision shall be made so that the successors and assigns of Spinco shall succeed to Spinco’s applicable rights and obligations set forth herein and therein. Furthermore, if Spinco or any of its successors or assigns
(e) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (f) transfers, licenses or conveys all or substantially all of its rights and
assets to any Person, then, and in each such case, Spinco may assign its rights, interests and obligations hereunder (in whole and not in part) to such Person without the prior written approval of MedImmune so long as in connection therewith Spinco
(i) also assigns to such Person all of its applicable rights, interests, and obligations under the other Transaction Agreements, and (ii) ensures that proper provision shall be made so that the successors and assigns of Spinco shall
succeed to Spinco’s rights and obligations set forth in this Agreement. Notwithstanding anything to the contrary set forth herein, no assignment or succession pursuant to this Section 7.7.1 shall relieve the assigning Party or predecessor
Party of its obligations hereunder. Upon any permitted assignment, the references in this Agreement to a Party shall also apply to any such assignee unless the context otherwise requires. 

  
 11 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 7.7.2.    Notwithstanding the foregoing, in the event a Party
assigns its rights or obligations under this Agreement or otherwise makes payments from a jurisdiction other than the jurisdiction in which such Party is organized (each, an “Assignment”), and immediately after such Assignment the
amount of Tax required to be withheld on any payment pursuant to this Agreement is greater than the amount of such Tax that would have been required to have been withheld absent such Assignment, then such increased withholding tax shall be borne by
the Party making such Assignment. 
 7.8.    Amendment. Except as expressly provided herein, this Agreement may
not be modified, amended, altered or supplemented except upon the execution and delivery of a written agreement executed by both Parties. 

7.9.    Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any
present or future Law, and if the rights or obligations of either Party under this Agreement will not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement shall be construed and
enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or
unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in
terms to such illegal, invalid or unenforceable provision as may be possible and reasonably acceptable to the Parties. 

7.10.    English Language. This Agreement shall be written and executed in, and all other communications under or
in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict in interpretation between the English version and such
translation, the English version shall control. 
 7.11.    Counterparts. This Agreement may be executed in any
number of counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. Delivery of an executed counterpart of a signature page of this Agreement
by facsimile or other electronic transmission shall be effective as delivery of a manually executed original counterpart of this Agreement. 

7.12.    Entire Agreement. This Agreement, together with the APA, the Transition Services Agreement (together with
the Schedules and Exhibits expressly contemplated thereby and attached thereto), the Disclosure Schedules, the other Transaction Agreements and the other agreements, certificates and documents delivered in connection with the APA or otherwise in
connection with the transactions contemplated hereby and thereby, contain the entire agreement between the Parties with respect to the transactions contemplated hereby or thereby and supersede all prior agreements, understandings, promises and
representations, whether written or oral, between the Parties with respect to the subject matter hereof and thereof. In the event of any inconsistency between any such Schedules and Exhibits and this Agreement, the terms of this Agreement shall
govern. In the event of any inconsistency between this Agreement and the other Transaction Agreements, the APA shall control. 

  
 12 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 7.13.    Construction. The Parties have participated jointly in
the negotiation and drafting of this Agreement and, in the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as jointly drafted by the Parties and no presumption or burden of proof shall arise
favoring or disfavoring any Party by virtue of the authorship of any provision of this Agreement. Except where the context otherwise requires, wherever used, the singular includes the plural, the plural the singular, the use of any gender shall be
applicable to all genders and the word “or” is used in the inclusive sense “and/or”. The table of contents and captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the
scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” or its variations as used herein does not limit the generality of any description preceding such term and shall be construed
as “including, without limitation.” The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party. Unless otherwise specified or
where the context otherwise requires, (a) references in this Agreement to any Article, Section, Schedule or Exhibit are references to such Article, Section, Schedule or Exhibit of this Agreement, and references to this “Agreement” are
references to this Agreement and all exhibits and schedules hereto; (b) references in any Section to any clause are references to such clause of such Section; (c) “hereof,” “hereto,” “hereby,” “herein”
and “hereunder” and words of similar import when used in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement; (d) references to a Person are also to its permitted successors and
assigns; (e) references to a Law include any amendment or modification to such Law and any rules, regulations or legally binding guidelines issued thereunder, in each case, as in effect at the relevant time of reference thereto;
(f) references to any agreement, instrument or other document in this Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently amended, replaced or supplemented from time to time, as so amended,
replaced or supplemented and in effect at the relevant time of reference thereto; (g) “extent” in the phrase “to the extent” means the degree to which a subject or other thing extends, and such phrase does not mean simply
“if”; (h) references to monetary amounts are denominated in United States Dollars; and (i) references to days (excluding Business Days) or months shall be deemed references to calendar days or months. 

[Signature Page Follows.] 

  
 13 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the Effective Date. 

 

			
	MedImmune, LLC	  	Viela Bio, Inc.
		
	By: [***]	  	By: /s/ Zhengbin (Bing) Yao
		
	Name: [***]	  	Name: Zhengbin (Bing) Yao
		
	Title: [***]	  	Title: CEO

  

  
 [Signature Page to
License Agreement] 
 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I)
IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 1 

4920 Patents 
  

							
	[***]	 	[***]	 	[***]	 	[***]
				
	[***]	 	[***]	 	[***]	 	[***]
				
	[***]	 	[***]	 	[***]	 	[***]

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 2 

MedImmune Internal R&D Tools 
  

			
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Schedule 3 

MedImmune Shared R&D Tools 
  

			
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.EX-10.16

 Exhibit 10.16 

CLINICAL SUPPLY AGREEMENT 

by and between 

ASTRAZENECA UK LIMITED 

and 
 VIELA BIO, INC.

 DATED AS OF FEBRUARY 23, 2018 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 TABLE OF CONTENTS 

 
  

									
	 1.
	  	DEFINITIONS AND INTERPRETATION	  	 	1	 
			
	 2.
	  	MANUFACTURE AND SUPPLY OF PRODUCT; PERFORMANCE OF SERVICES	  	 	9	 
				
		  	2.1.	  	Scope of Agreement	  	 	9	 
		  	2.2.	  	Commercial Agreement	  	 	9	 
		  	2.3.	  	Requirements	  	 	9	 
		  	2.4.	  	Specifications; Change Control	  	 	9	 
		  	2.5.	  	Services	  	 	11	 
		  	2.6.	  	Supply Chain Governance	  	 	11	 
		  	2.7.	  	Capacity	  	 	11	 
		  	2.8.	  	Performance by Affiliates	  	 	11	 
			
	 3.
	  	CLINICAL SUPPLY SCHEDULE	  	 	11	 
				
		  	3.1.	  	Clinical Supply Plan	  	 	11	 
		  	3.2.	  	Existing Materials	  	 	12	 
			
	 4.
	  	PURCHASE ORDERS	  	 	12	 
				
		  	4.1.	  	Purchase Orders	  	 	12	 
		  	4.2.	  	AstraZeneca’s Fulfillment of Purchase Orders	  	 	12	 
		  	4.3.	  	Purchase Order Acceptance and Confirmation	  	 	12	 
		  	4.4.	  	Terms and Conditions	  	 	12	 
		  	4.5.	  	Accuracy	  	 	13	 
		  	4.6.	  	Suppliers	  	 	13	 
			
	 5.
	  	DELIVERY	  	 	13	 
				
		  	5.1.	  	Delivery	  	 	13	 
		  	5.2.	  	Delivery Date	  	 	13	 
		  	5.3.	  	Installments	  	 	13	 
		  	5.4.	  	Documentation	  	 	13	 
		  	5.5.	  	Quantity	  	 	13	 
		  	5.6.	  	Packaging	  	 	14	 
		  	5.7.	  	Shipping/Insurance	  	 	14	 
			
	 6.
	  	RISK AND TITLE	  	 	14	 
				
		  	6.1.	  	Risk and Title	  	 	14	 
			
	 7.
	  	PRICE	  	 	14	 
				
		  	7.1.	  	Price of Supplied Products	  	 	14	 
		  	7.2.	  	Supply Price Changes	  	 	14	 
		  	7.3.	  	Reporting of [***]; True-Up	  	 	14	 
		  	7.4.	  	Services Fees	  	 	14	 
		  	7.5.	  	Currency	  	 	14	 
		  	7.6.	  	Financial Records	  	 	15	 
		  	7.7.	  	Financial Audits	  	 	15	 
		  	7.8.	  	Audit Dispute	  	 	15	 

  
 i 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

									
			
	 8.
	  	INVOICING AND PAYMENT	  	 	15	 
				
		  	8.1.	  	Invoicing	  	 	15	 
		  	8.2.	  	Payment	  	 	15	 
		  	8.3.	  	Failure to Timely Pay	  	 	16	 
			
	 9.
	  	REPRESENTATIONS AND WARRANTIES	  	 	16	 
				
		  	9.1.	  	Representations and Warranties	  	 	16	 
		  	9.2.	  	Warranty by AstraZeneca	  	 	17	 
			
	 10.
	  	NON-CONFORMING PRODUCT AND SHORTFALLS	  	 	18	 
				
		  	10.1.	  	Conforming Products	  	 	18	 
		  	10.2.	  	Shortfall or Non-Conforming Product	  	 	18	 
		  	10.3.	  	Remedies for Shortfall or Non-Conformance	  	 	18	 
		  	10.4.	  	Return or Destruction of Non-Conforming Products	  	 	19	 
		  	10.5.	  	Disagreement	  	 	19	 
		  	10.6.	  	Referral to Independent Expert	  	 	19	 
			
	 11.
	  	REGULATORY MATTERS	  	 	19	 
				
		  	11.1.	  	Clinical Quality Agreement	  	 	19	 
		  	11.2.	  	Adverse Event Reporting	  	 	19	 
		  	11.3.	  	Recalls	  	 	19	 
			
	 12.
	  	COMPLIANCE	  	 	20	 
				
		  	12.1.	  	Compliance with Applicable Laws	  	 	20	 
		  	12.2.	  	Anti-Corruption Laws	  	 	20	 
			
	 13.
	  	CONFIDENTIALITY AND INTELLECTUAL PROPERTY	  	 	20	 
				
		  	13.1.	  	Confidentiality	  	 	20	 
		  	13.2.	  	Permitted Disclosure	  	 	21	 
		  	13.3.	  	Press Releases; Public Announcements	  	 	22	 
		  	13.4.	  	Injunctive Relief	  	 	22	 
		  	13.5.	  	Return or Destruction of Confidential Information	  	 	22	 
		  	13.6.	  	Permitted Retention of Confidential Information	  	 	23	 
		  	13.7.	  	Intellectual Property	  	 	23	 
		  	13.8.	  	Manufacturing Technology	  	 	23	 
			
	 14.
	  	SPECIAL EQUIPMENT	  	 	24	 
				
		  	14.1.	  	Purchase of Special Equipment	  	 	24	 
		  	14.2.	  	Ownership of Special Equipment	  	 	25	 
		  	14.3.	  	Maintenance of Special Equipment	  	 	25	 
		  	14.4.	  	Exclusive Use	  	 	25	 
			
	 15.
	  	INDEMNITIES	  	 	25	 
				
		  	15.1.	  	Indemnification of AstraZeneca	  	 	25	 
		  	15.2.	  	Indemnification of SPINCO	  	 	25	 
		  	15.3.	  	Exceptions and Limitations on Indemnification and Recalls	  	 	25	 
		  	15.4.	  	Indemnification Procedures	  	 	26	 

  
 ii 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

									
			
	 16.
	  	LIABILITY	  	 	26	 
				
		  	16.1.	  	Disclaimer	  	 	26	 
		  	16.2.	  	Limitation of Liability	  	 	26	 
		  	16.3.	  	Maximum Liability	  	 	26	 
		  	16.4.	  	Recovery of Damages.	  	 	27	 
			
	 17.
	  	INSURANCE	  	 	27	 
				
		  	17.1.	  	Insurance	  	 	27	 
			
	 18.
	  	FORCE MAJEURE	  	 	27	 
				
		  	18.1.	  	Force Majeure	  	 	27	 
			
	 19.
	  	TERM AND TERMINATION	  	 	27	 
				
		  	19.1.	  	Term	  	 	27	 
		  	19.2.	  	Early Termination	  	 	28	 
			
	 20.
	  	EFFECT OF TERMINATION	  	 	28	 
				
		  	20.1.	  	Effect of Termination	  	 	28	 
		  	20.2.	  	Technology Transfer	  	 	29	 
		  	20.3.	  	Wind-down Period	  	 	30	 
		  	20.4.	  	Survival	  	 	30	 
			
	 21.
	  	INDEPENDENT CONTRACTORS	  	 	30	 
				
		  	21.1.	  	Independent Contractors.	  	 	30	 
			
	 22.
	  	NOTICES	  	 	30	 
				
		  	22.1.	  	Notice Requirements	  	 	30	 
		  	22.2.	  	Day-to-day Communications	  	 	31	 
			
	 23.
	  	MISCELLANEOUS	  	 	31	 
				
		  	23.1.	  	No Set-Off	  	 	31	 
		  	23.2.	  	Variation and Waiver	  	 	31	 
		  	23.3.	  	Counterparts	  	 	32	 
		  	23.4.	  	Invalidity	  	 	32	 
		  	23.5.	  	Headings	  	 	32	 
		  	23.6.	  	Assignment	  	 	32	 
		  	23.7.	  	Subcontracting	  	 	33	 
		  	23.8.	  	No License	  	 	33	 
		  	23.9.	  	No Rights of Third Parties	  	 	33	 
		  	23.10.	  	Joint Drafting	  	 	34	 
		  	23.11.	  	Entire Agreement	  	 	34	 
		  	23.12.	  	Governing Law, Jurisdiction and Dispute Resolution	  	 	34	 
		  	23.13.	  	Delivery of Agreement	  	 	35	 

  
 iii 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 THIS CLINICAL SUPPLY AGREEMENT (this “Supply Agreement”) is dated
February 23, 2018 (the “Effective Date”) 
 BETWEEN: 
  

	(1)	 ASTRAZENECA UK LIMITED, a company incorporated under the laws of England and Wales, whose registered
office is at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, Cambridgeshire, United Kingdom, CB2 0AA and is a member of the AstraZeneca group of companies (“AstraZeneca”); and 

 

	(2)	 VIELA BIO, INC., a Delaware corporation, whose registered office is at 1209 Orange Street, Wilmington,
New Castle Country, Delaware, 19801 (“SPINCO”); 

 (each a “Party”, collectively the
“Parties”). 
 BACKGROUND: 
  

	(A)	 WHEREAS, certain Affiliates of AstraZeneca and SPINCO have entered into that certain Asset Purchase Agreement,
dated February 23, 2018 (the “APA”), pursuant to which MedImmune, LLC, MedImmune Limited and AstraZeneca Collaboration Ventures, LLC have agreed to sell certain assets to SPINCO on the terms and subject to the conditions set
forth therein; 

  

	(B)	 WHEREAS, in accordance with the terms and conditions of the APA, AstraZeneca and SPINCO have agreed to enter
into an agreement pursuant to which AstraZeneca will supply to SPINCO, and SPINCO will purchase from AstraZeneca, Supplied Products for clinical use by SPINCO and related services; 

 

	(C)	 WHEREAS, AstraZeneca and SPINCO have also agreed to enter into the Clinical Quality Agreement;

  

	(D)	 NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows: 

 

	1.	 DEFINITIONS AND INTERPRETATION 

 

	1.1.	 Unless otherwise specifically provided herein, capitalized words and phrases used in this Supply
Agreement shall have the meaning ascribed to them in the APA. In addition, the following words and expressions shall have the following meanings: 

“Account Manager” has the meaning given in Clause 2.6; 

“Additional Quantity” has the meaning given in Clause 4.3; 

“Affiliate” means, with respect to a Person, any other Person that controls, is controlled by, or is under common control with
such Person. For purposes of this Supply Agreement, a Person will be deemed to control another Person if it owns or controls, directly or indirectly, more than 50% of the equity securities of such other Person entitled to vote in the election of
directors (or, in the case that such other Person is not a corporation, for the election of the corresponding managing authority), or otherwise has the power to direct the management and policies of such other Person. The Parties acknowledge that in
the case of certain entities organized under the laws of certain countries outside the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than 50%, and that in such case such lower percentage will be
substituted in the preceding sentence; provided that such foreign investor 

  
 1 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
has the power to direct the management and policies of such entity. Notwithstanding the foregoing or anything else to the contrary herein or in the APA, for purposes of this Supply Agreement,
neither Party shall be considered an Affiliate of the other Party, notwithstanding the fact that SPINCO may be considered an affiliate of AstraZeneca under the terms of other contracts to which AstraZeneca or its respective other affiliates may be a
party; 
 “Anti-Corruption Laws” means the United States Foreign Corrupt Practices Act, the UK Bribery Act 2010 and any
other applicable anti-corruption laws and laws for the prevention of fraud, racketeering, money laundering or terrorism; 

“APA” has the meaning given in the “Background” heading at the start of this Supply Agreement; 

“Apparent Defects” has the meaning given in Clause 10.2; 

“Applicable Law” means all applicable laws, rules and regulations, including any applicable rules, regulations, guidelines or
other requirements of Regulatory Authorities, that may be in effect from time to time; 
 “Arising IPR” has the meaning
given in Clause 13.7(a); 
 “Assignment” has the meaning given in Clause 23.6; 

“Auditor” has the meaning given in Clause 7.8; 

“AZ Group” means AstraZeneca and its Affiliates; 

“AZ Supplier” means any Third Parties engaged by AstraZeneca to provide Materials and perform Manufacturing services relevant
to the Manufacture of Supplied Products or perform Services;  
 “Background IPR” means all Intellectual
Property Rights, results, data, inventions and information owned by either Party (or owned by a Third Party licensor but licensed to a Party with the right to disclose or sub-license) prior to the Effective
Date; 
 “Biologics License Application” or “BLA” means, with respect to the Product, a Biologics License
Application (as that term is defined in section 351(a) of the Public Health Service Act) or a New Drug Application (as that term is defined in section 505(b) of the FD&C Act), filed with the FDA in the United States with respect to the Product,
or any corresponding foreign application or similar application or submission filed with a Regulatory Authority to obtain marketing approval for a biological or pharmaceutical product in a country or group of countries; 

“Breaching Party” has the meaning given in Clause 19.2; 

“Calendar Quarter” means each successive period of three (3) calendar months commencing on January 1, April 1,
July 1 and October 1; provided, that the first Calendar Quarter of the Supply Term shall commence on the Effective Date and end on the day immediately prior to the first to occur of January 1, April 1, July 1 or October 1
after the Effective Date, and the last Calendar Quarter shall end on the last day of the Supply Term; 
 “Calendar Year”
means each successive period of twelve (12) calendar months commencing on January 1 and ending on December 31, except that the first Calendar Year of the Supply Term shall commence on the Effective Date and end on December 31 of
the year in which the Effective Date occurs and the last Calendar Year of the Supply Term shall commence on January 1 of the year in which the Supply Term ends and end on the last day of the Supply Term; 

  
 2 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 “Certificate of Analysis” means the certificate of analysis to accompany
each Supplied Product delivered to SPINCO, which certifies that the Supplied Product has been Manufactured and tested in compliance with its Specification; 

“cGMP” means FDA’s current good manufacturing practices, as specified in the United States Code of Federal Regulations
(CFR) 21 CFR Parts 11, 210, 211, 600-680 and 820 and FDA’s guidance documents and all successor regulations and guidance documents thereto, and European Commission Directive 2003/94/EC, Eudralex Volume 4,
and 93/42/EEC; 
 “Clinical Quality Agreement” means a quality assurance agreement to be agreed between the Parties pursuant
to Clause 11.1, which shall include quality responsibilities with respect to, among other things, release testing, stability testing, access to IMP Dossier and record retention requirements, as such agreement may be amended or replaced by agreement
between the Parties in writing from time to time; 
 “Clinical Supply Plan” has the meaning given in Clause 3.1(a); 

“CMC Data” means the chemistry, manufacturing and controls data required by Applicable Law to be included or referenced in, or
that otherwise supports, an IND or BLA for the Product; 
 “Commercial Supply Agreement” has the meaning given in Clause
2.2; 
 “Commercially Reasonable Efforts” means, with respect to the Manufacture and supply of Supplied Products provided
hereunder and performance of Services with respect thereto, the carrying out of such activities using efforts and resources consistent with the efforts and resources used in the biopharmaceutical industry by a company of comparable size and
financial resources in connection with the manufacturing of products that are of similar status and stage of development; 

“Complaining Party” has the meaning given in Clause 19.2; 

“Confidential Information” has the meaning given in Clause 13.1; 

[***]; 
 “Delivery
Location” means the applicable AstraZeneca Manufacturing facility or such other delivery location mutually agreed upon by the Parties; 

“Drug Product” means the Product in final form, including Product that has been Manufactured from the successful process
performance qualification (PPQ) run that confirms the process design and demonstrates that the Manufacturing process performs as expected; 

“Drug Substance” means the Product that has been formulated and is in final form except for fill and finish processing, which
includes a final formulation step, including Product that has been Manufactured from the successful process performance qualification (PPQ) run that confirms the process design and demonstrates that the Manufacturing process performs as expected;

 “Effective Date” has the meaning given in the introductory paragraph hereto; 

“Existing Materials” has the meaning given in Clause 3.2; 

  
 3 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 “Facility Change” has the meaning given in Clause 2.4(f); 

“FD&C Act” means the United States Federal Food, Drug, and Cosmetic Act, as amended and may be amended from time to
time, and the rules and regulations promulgated thereunder; 
 “FDA” means the United States Food and Drug Administration,
or any successor thereto; 
 “Firm Order” has the meaning given in Clause 3.1; 

“Force Majeure” means any circumstances beyond a Party’s reasonable control, including accidents, civil disorders or
commotions, riot, war, malicious damage, acts of terrorism, acts of God, Governmental Authority-imposed energy or other conservation measures, explosions, failure of utilities by the provider, disease, pandemic, quarantine, or theft; 

“FTE Rate” means an annual rate [***] for the time of an employee for a full-time equivalent (“FTE”) person
year [***] of work, pro-rated on a daily basis. Without limiting the above, [***]; 

“Governmental Authority” means any nation or government or governmental or regulatory body thereof, or political subdivision
thereof, whether federal, state, local or foreign, or any agency, instrumentality or authority thereof, or any court or arbitrator (public or private) or any other entity exercising executive, judicial, legislative, regulatory or administrative
functions of or pertaining to regulation or to government; 
 “IFRS” means the International Financial Reporting Standards;

 “IMP Dossier” means an Investigational Medicinal Product Dossier; 

“IND” means an Investigational New Drug Application submitted under Section 505(i) of the FD&C Act, or an analogous
application or submission with any analogous agency or Regulatory Authority outside of the United States for the purposes of obtaining permission to conduct clinical trials; 

“Indemnifying Party” has the meaning given in Clause 15.4; 

“Indemnitee” has the meaning given in Clause 15.4; 

“Independent Expert” has the meaning given in Clause 10.5; 

“Indirect Taxes” means value added taxes, sales taxes, consumption taxes and other similar Taxes that are required to be
disclosed on an Indirect Tax invoice. 
 “Initial Term” has the meaning given in Clause 19.1; 

“Intellectual Property Rights” means rights in Confidential Information including
Know-How, along with all Patents, trademarks, service marks, trade names, design rights, copyright (including rights in computer software) and any similar or equivalent rights or property or forms of
protection in any part of the world, whether registered or not, together with the right to apply for the registration of any such rights; 

“IT Media” has the meaning given in Clause 13.6; 

“Know-How” means any data, results, technology, business or financial information or
information of any type whatsoever, in any tangible or intangible form, including know-how, practices, techniques, methods, assays, processes, protocols, inventions, discoveries,

  
 4 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 
improvements, developments, specifications, formulations, formulae, algorithms, marketing reports, business plans, expertise, technology, test data (including pharmacological, biological,
chemical, biochemical, medical, toxicological, preclinical, and clinical test data and any other research or development data), standard operating procedures, manufacturing records, stability data and other study data and procedures; 

“Labelling” means all labels, package inserts, carton imprints and all other markings on packaging for the Supplied Products
that are defined as labels or labelling under any relevant Regulatory Approval (excluding, for the avoidance of doubt, any transportation packaging); 

“Latent Defects” has the meaning given in Clause 10.2; 

“Law” has the meaning set forth in the APA. 

“Losses” means any and all liabilities, claims, demands, causes of action, damages, losses and expenses, including interest,
penalties and reasonable legal and professional fees and disbursements; 
 “Manufacture” means all activities related to the
production, manufacture, processing, filling, finishing, packaging and labelling (as contemplated by Clause 5.6), inter-site shipping and holding of a Supplied Product or any intermediate thereof (and “Manufactured” and
“Manufacturing” shall be interpreted accordingly); 
 “Manufacturing Change” has the meaning given in
Clause 2.4; 
 “Materials” means, with respect to a Supplied Product, any materials used by AstraZeneca to Manufacture and
supply the Supplied Product, including in the case of the Product, the active ingredient therein; 
 “MedImmune Manufacturing
Technology” means any Know-How that (a) is not generally known, (b) is owned or controlled by AstraZeneca or its Affiliates as of the Effective Date or during the Supply Term, and
(c) is necessary or used by AstraZeneca for Manufacture of the Supplied Products hereunder; 
 “Minimum Order Size”
means the minimum size for any Purchase Order as specified in the Clinical Supply Plan; 
 “Modified Amount” has the meaning
given in Clause 3.1(b); 
 “New SPINCO IPR” has the meaning given in Clause 13.7(a); 

“Non-Conforming Product” or
“Non-Conformance” means any Supplied Product which, at the time of delivery to the Delivery Location, does not conform with the requirements of Clause 10.1; 

“Notice Period” has the meaning given in Clause 19.2; 

“Out-of-Pocket Costs” means, with respect to
any Services or Technology Transfer, (a) any amounts paid to Third Parties (including costs incurred by AstraZeneca or its Affiliates under Third Party contracts); (b) shipping and transportation costs (including the cost of any insurance
related thereto), duties and Taxes; (c) travel-related costs from mutually-agreed-upon travel; (d) costs or expenses incurred by AstraZeneca, its Affiliates or subcontractors for the extraction, conversion and transfer of data;
(e) any costs and expenses described in a Services Schedule that are not included as Services Fees; and (f) any other actual, reasonably incurred, documented,
out-of-pocket costs and expenses, in each case (a) through (f), directly incurred by AstraZeneca and its Affiliates in providing such Services or Technology
Transfer; 

  
 5 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 “Party” and “Parties” have the meanings given in the
preamble hereto; 
 “Person” means any individual, corporation, limited liability company, partnership, firm, joint venture,
association, joint-stock company, trust, unincorporated organization, Governmental Authority or other entity; 
 “Personnel”
means the employees, officers, agents and contractors of a Party or (where, the context requires, those of a Party’s Affiliates); 

“Pharmacovigilance Agreement” means the pharmacovigilance agreement for the Supplied Product to be mutually agreed upon
between the Parties; 
 “Placebo” has the meaning given in the definition of “Supplied Product”; 

“Product” has the meaning given in the definition of “Supplied Product”; 

“Purchase Order” has the meaning given in Clause 4.1; 

“Regulatory Approval” means, with respect to the Product and a particular country, any and all approvals (including approvals
of Biologics License Applications), licenses, registrations or authorizations of any Regulatory Authority necessary to develop, manufacture or commercialize the Product in such country; 

“Regulatory Authority” means any applicable supra-national, federal, national, regional, state, provincial or local regulatory
agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the exploitation of Supplied Products anywhere in the world, including the FDA in the United States; 

“Remediation Plan” has the meaning given in Clause 18.2; 

“Representation” has the meaning given in Clause 23.11; 

“Representatives” has the meaning given in Clause 13.2; 

“Required Manufacturing Change” has the meaning given in Clause 2.4; 

“Services” means the activities to be performed by AstraZeneca as described in a Services Schedule agreed pursuant to
Clause 2.5; 
 “Services Fees” has the meaning given in Clause 7.4; 

“Services Schedule” has the meaning given in Clause 2.5; 

“Shortfall” means the quantity of a Supplied Product actually delivered to SPINCO that is less than the quantity set out in
the Purchase Order unless the actual quantity delivered is only [***] than the amount ordered; 
 “SKU” means stock keeping
unit; 

  
 6 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 “Special Equipment” means equipment to be provided by SPINCO to
AstraZeneca, or purchased or otherwise acquired by AstraZeneca at SPINCO’s expense, where such equipment is not presently under the control of AstraZeneca, is reasonably required by AstraZeneca to perform its obligations under this Supply
Agreement, and is not otherwise required by AstraZeneca or its subcontractors for Manufacturing of products other than Supplied Products; 

“Specification” means, on a Supplied
Product-by-Supplied Product basis, the written specifications for the characteristics and quality of such Supplied Product, as set forth in the Clinical Quality
Agreement; 
 “SPINCO IP” means (a) the Assigned Intellectual Property and rights in or to other Acquired Assets (as
such terms are defined in the APA), and (b) any other intellectual property rights, in each case ((a) and (b)), owned or controlled by SPINCO or its Affiliates (other than pursuant to a license or grant of rights from AstraZeneca or its
Affiliates) at any time during the Supply Term that are necessary for the performance of AstraZeneca’s obligations hereunder; 

“Supplied Product” means any (a) product containing as its active ingredient the molecule known as Inebilizumab
(previously known as MEDI-551) as a sole active ingredient with the same formulation, method of delivery, and Specification as such product is being developed by the AZ Group as of the Effective Date (the
“Product”), or (b) matching placebo for the Product as described in the Specification therefor (the “Placebo”); 

“Supply Agreement” has the meaning given in the preamble hereto; 

“Supply Price” has the meaning given in Clause 7.1; 

“Supply Term” has the meaning given in Clause 19.1; 

“Taxes” means and includes all forms of taxation, levy, impost or duty and any similar charge, contribution, deduction or
withholding and all penalties, charges, surcharges, fines, costs and interest included in, or relating to, any of the foregoing or to any obligation in respect of any of the foregoing; 

“Technology Recipient” has the meaning in Clause 20.2; 

“Technology Transfer” has the meaning in Clause 20.2; 

“Third Party” means any Person other than AstraZeneca, SPINCO and their respective Affiliates and permitted successors and
assigns; 
 “Third Party Claim” has the meaning given in Clause 15.1; and 

“True-Up Payment” has the meaning given in Clause 7.3. 

In this Supply Agreement, except to the extent expressly provided otherwise herein: 

 

	 	(a)	 when a reference is made in this Supply Agreement to a Clause, Exhibit or Schedule, such reference is to a
Clause of or an Exhibit or Schedule to this Supply Agreement respectively, and all Exhibits and Schedules to this Supply Agreement form a part hereof for all purposes; 

 

	 	(b)	 the contents page and headings are included for convenience only and shall not affect the interpretation or
construction of this Supply Agreement; 

  

	 	(c)	 any reference to a Party or the Parties is to a Party or the Parties (as the case may be) to this Supply
Agreement and shall include any permitted assignees of a Party; 

  
 7 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(d)	 where any Party gives in this Supply Agreement any indemnity in favor of the other Party the obligation of the
indemnifying Party shall be to make the relevant payment forthwith in full on demand and without any set-off, counterclaim or other deduction (except to the extent required by Applicable Laws);

  

	 	(e)	 any reference to a Person is also to such Person’s successors and permitted assigns;

  

	 	(f)	 any use of the masculine, feminine or neuter gender respectively includes the other genders and any reference
to the singular includes the plural (and vice versa); 

  

	 	(g)	 the words including, includes or include, whenever used in this Supply Agreement, are deemed to be followed by
the words “without limitation”; in particular means “in particular but without limitation”, “such as” means “such as without limitation” and other general words shall not be given a restrictive interpretation
by reason of their being preceded or followed by words indicating a particular class of acts, matters or things; 

  

	 	(h)	 any reference to “US Dollars” or “$” is to the lawful currency from time to time of the
United States of America; 

  

	 	(i)	 the word “or” is used in the inclusive sense, as in “and/or”; 

 

	 	(j)	 any reference to a statute or statutory provision includes any successor legislation thereto, regulations
promulgated thereunder, any consolidation or re-enactment, modification or replacement thereof, any statute or statutory provision of which it is a consolidation,
re-enactment, modification or replacement and any subordinate legislation in force under any of the same from time to time; 

 

	 	(k)	 all terms defined in this Supply Agreement shall have the defined meanings when used in any certificate or
other document made or delivered pursuant hereto, unless otherwise defined in such certificate or other document, and all definitions contained herein apply both to the singular and plural forms of such terms; 

 

	 	(l)	 any reference to writing shall include any modes of reproducing words in a legible and non-transitory form (excluding short-message-service (SMS)), such as email, facsimile, and other electronic communications; 

  

	 	(m)	 any reference to an obligation of AstraZeneca shall be deemed to be an obligation owed to SPINCO, and any
reference to an obligation of SPINCO shall be deemed to be an obligation owed to AstraZeneca; 

  

	 	(n)	 any obligation on a Party not to do something includes an obligation not to allow that thing to be done; and

  

	 	(o)	 reference to any date or time is a reference to such date or time in Washington, D.C., United States of
America. 

  

	1.2.	 Unless otherwise expressly stated or the context otherwise requires, in case of a conflict between:

  

	 	(a)	 any Schedules or any Exhibit and the provisions of the main body (Clauses 1 through 23) of this Supply
Agreement, such terms of this Supply Agreement shall control; 

  

	 	(b)	 any Purchase Order and this Supply Agreement, this Supply Agreement shall control; and 

  
 8 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(c)	 the provisions of the Clinical Quality Agreement and the provisions of this Supply Agreement, the provisions of
this Supply Agreement shall prevail, except that with respect to matters related to quality, the Clinical Quality Agreement shall prevail. 

  

	2.	 MANUFACTURE AND SUPPLY OF PRODUCT; PERFORMANCE OF SERVICES 

 

	2.1.	 Scope of Agreement. This Supply Agreement covers (a) the Manufacture and supply of
Supplied Products by AstraZeneca or its Affiliates to SPINCO for SPINCO’s clinical use of such Supplied Products and (b) the performance by AstraZeneca or its Affiliates of the Services. Neither SPINCO nor any of its Affiliates,
licensees, sublicensees, agents or representatives shall (a) label or re-label (or cause to be labeled or re-labeled) or supply any Supplied Product for
commercial sale or for any use or purpose other than for clinical use or (b) sell or transfer for value (or cause to be sold or transferred for value) to any Third Party any Supplied Product. For the avoidance of doubt, the supply by
AstraZeneca of the Product for commercial use by SPINCO is outside the scope of this Supply Agreement, and may be separately negotiated between the Parties.  

 

	2.2.	 Commercial Agreement. Upon SPINCO’s request, the Parties will negotiate in good faith
and deal fairly in entering into a separate commercial supply agreement for the Product based on the terms and conditions customarily used by AstraZeneca in similar agreements with parties outside of the AZ Group (any such agreement, the
“Commercial Supply Agreement”). The Parties will seek to execute, or AstraZeneca shall cause its Affiliate to execute, the Commercial Supply Agreement promptly following commencement of such negotiations and in any event within six
months of such commencement. 

  

	2.3.	 Requirements. During the Supply Term, SPINCO shall purchase, and AstraZeneca shall, or shall
cause its Affiliates to, Manufacture and supply, all of SPINCO’s requirements for Supplied Products in accordance with Clauses 3 and 4; provided that: 

  

	 	(a)	 the timing of supply and quantity of Supplied Products to be supplied by AstraZeneca will reflect the facility
schedule availability, conditions and lead times for Drug Substance and Drug Product; and 

  

	 	(b)	 the timing of supply and quantity of Supplied Products to be supplied by AstraZeneca will reflect the
scheduling lead time required by any AZ Suppliers. 

  

	2.4.	 Specifications; Change Control. 

 

	 	(a)	 AstraZeneca shall Manufacture or cause its Affiliate to Manufacture each Supplied Product in accordance with
all Applicable Laws (including cGMP), the Clinical Quality Agreement, and the Specification for such Supplied Product. Each Supplied Product provided by AstraZeneca pursuant to this Supply Agreement shall conform to the Specification for such
Supplied Product at the time of delivery to the Delivery Location. 

  

	 	(b)	 Procedures governing changes to the Specification or changes in the Manufacturing process, Manufacturing
facility(ies) or Materials used by AstraZeneca to Manufacture any Supplied Product (each a “Manufacturing Change”) are set out in the Clinical Quality Agreement. Any Manufacturing Change shall be implemented in accordance with the
provisions of the Clinical Quality Agreement. 

  

	 	(c)	 If a Regulatory Authority requires any Manufacturing Change or AstraZeneca acting in good faith, determines
that any Manufacturing Change is otherwise required to comply with regulatory requirements (each a “Required Manufacturing Change”), the Parties shall, each acting reasonably and in good faith, endeavor to agree

  
 9 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
promptly on an action plan to implement such change; provided that if SPINCO, acting in good faith, disagrees with any AstraZeneca determination that a Manufacturing Change is required,
AstraZeneca shall consider SPINCO’s comments in good faith. The costs and expenses of implementing such change shall be borne solely by SPINCO; provided that, if and to the extent such Manufacturing Change is being made for the benefit of
Supplied Products and other products that are Manufactured by AstraZeneca then SPINCO shall bear an equitable proportion of such costs and expenses. 

  

	 	(d)	 From time to time during the Supply Term, SPINCO may request a Manufacturing Change other than a Required
Manufacturing Change and AstraZeneca will consider any such requests in good faith. If AstraZeneca provides consent (such consent not to be unreasonably withheld, delayed or conditioned), it will provide SPINCO with an estimate of the timeframe and
costs and expenses for implementation of the change, including whether any such costs and expenses (or a portion thereof) shall be [***]. If the Manufacturing Change is implemented, unless otherwise agreed, SPINCO shall bear the costs and expenses
of the change. Where a Manufacturing Change is required by SPINCO and such change results in rendering obsolete any inventory of Supplied Products or Materials used in the Manufacture of the Supplied Products, SPINCO shall bear the costs and
expenses of such write-off (including waste disposal costs) for Supplied Products and Materials that AstraZeneca is not able to utilize elsewhere; provided that AstraZeneca will use Commercially Reasonable
Efforts to utilize such Materials and SPINCO will provide AstraZeneca with reasonable assistance in doing so.  

  

	 	(e)	 From time to time during the Supply Term, AstraZeneca may give notice to SPINCO that AstraZeneca intends to
implement a Manufacturing Change other than a Required Manufacturing Change subject to Clause 2.4(c) or a Facility Change subject to Clause 2.4(f); provided that except as provided in this Supply Agreement or the Clinical Quality Agreement,
AstraZeneca shall not implement a Manufacturing Change pursuant to this Clause 2.4(e) unless SPINCO has given its consent to such change (such consent not to be unreasonably withheld, delayed or conditioned). If AstraZeneca requests such a
Manufacturing Change, unless otherwise agreed, AstraZeneca shall bear the costs and expenses of AstraZeneca implementing such change and the reasonable and verifiable costs (including with respect to the establishment of comparability) incurred by
SPINCO arising as a direct and unavoidable result of such change; provided that such costs shall not include any costs incurred by SPINCO with respect to supplementary regulatory filings arising from such change. 

 

	 	(f)	 From time to time during the Supply Term, AstraZeneca may give notice to SPINCO that AstraZeneca intends to
change the geographic location of the Manufacturing site(s) used by AstraZeneca to Manufacture a Supplied Product (a “Facility Change”). Unless otherwise agreed to by the Parties, such notice must be provided to SPINCO at least
thirty (30) months prior to the anticipated Facility Change. AstraZeneca will not provide written notice of any Facility Change prior to the first anniversary of the Effective Date. Any Facility Change will be made in AstraZeneca’s sole
discretion; provided that in implementing a Facility Change, AstraZeneca shall use its best efforts to minimize any adverse impact on the IND or Biologics License Application or Regulatory Approvals for the Product. AstraZeneca shall be responsible
for the technology transfer and other costs and expenses of AstraZeneca implementing a Facility Change and the reasonable and verifiable costs (including with respect to the establishment of comparability) incurred by SPINCO arising as a direct and
unavoidable result of such Facility Change, in each case 

  
 10 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
pursuant to this Clause 2.4(f); provided that such costs shall not include any costs incurred by SPINCO with respect to supplementary regulatory filings arising from such change.

  

	2.5.	 Services. The Parties acknowledge and agree that, during the Supply Term, SPINCO may require
services in connection with the activities set forth on Schedule 1 for the Product [***]. If requested by SPINCO, AstraZeneca and SPINCO shall negotiate a services schedule detailing the Services to be provided and the Services Fees payable in
connection with one or more such activities (each, a “Services Schedule”). Upon execution of a Services Schedule, AstraZeneca shall use Commercially Reasonable Efforts to perform the Services in accordance with the applicable
Services Schedule. 

  

	2.6.	 Supply Chain Governance. The Parties will each designate an account manager (the “Account
Managers”) to discuss supply issues relating to the Supplied Products and the performance of the Services. 

  

	2.7.	 Capacity. AstraZeneca shall or shall cause its Affiliates to devote sufficient manufacturing
capacity to be capable of manufacturing and supplying Supplied Products to SPINCO in accordance with the Clinical Supply Plan. In the event that the Materials and/or Manufacturing capacity required to Manufacture and deliver the Supplied Products to
SPINCO in a timely manner in accordance with Firm Orders are in short supply, AstraZeneca shall (i) notify SPINCO promptly of such shortage and the Parties shall promptly meet to discuss the shortage and (ii) within [***] after such
notification, AstraZeneca shall provide a written plan of action stating in reasonable detail its proposed measures to resolve such shortage and the date such shortage is expected to end. AstraZeneca shall use Commercially Reasonable Efforts to
minimize the duration of any shortage so as to avoid a Shortfall.  

  

	2.8.	 Performance by Affiliates. AZ shall have the right to perform all or any of its obligations under
this Agreement through any of its Affiliates provided that AZ shall remain responsible for the performance of such Affiliate as if such obligations were performed by AZ itself. 

 

	3.	 CLINICAL SUPPLY SCHEDULE 

 

	3.1.	 Clinical Supply Plan. 

 

	 	(a)	 Within thirty (30) days after the Effective Date and thereafter at six (6) month intervals, the
Parties shall (a) discuss in good faith the projected clinical studies to be performed by or on behalf of SPINCO with respect to the Product during the subsequent twenty-four (24) month-period and the Supplied Products needed for such
clinical studies, and (b) agree upon a supply plan (the “Clinical Supply Plan”), which shall specify the amount of Supplied Products, on SKU by SKU basis, to be provided to SPINCO hereunder and timelines for provision of such
Supplied Products in order to meet the needs of the clinical studies for each of the twenty-four (24) months covered by the Clinical Supply Plan. 

  

	 	(b)	 The quantities of Supplied Products to be provided to SPINCO as designated in the Clinical Supply Plan for the
[***] of the Clinical Supply Plan shall constitute a firm order for such Supplied Products and a binding order commitment on SPINCO to submit Purchase Orders for such quantities (each, a “Firm Order”). SPINCO may update the quantity
of Supplied Products set forth in the Clinical Supply Plan [***] including to reflect adjustments in enrollment rates or other circumstances; provided further that, with respect to such change, unless AstraZeneca agrees to permit a further
modification in its reasonable discretion, the quantities for a particular Supplied Product for [***] (collectively, a “Modified Amount”). 

  
 11 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	3.2.	 Existing Materials. The Parties acknowledge that, pursuant to the terms and subject to the
conditions of the APA, SPINCO has acquired AstraZeneca’s inventory of process performance qualification (PPQ) Drug Substance of the Product that is in AstraZeneca’s possession as of the Effective Date (the “Existing
Materials”). AstraZeneca shall continue to store the Existing Materials in a manner that is consistent with the manner such Existing Materials are being stored by the AZ Group as of the Effective Date, at SPINCO’s cost and expense.
AstraZeneca shall use such Existing Materials to Manufacture and supply Supplied Products under this Supply Agreement and, if and to the extent provided for in the Commercial Supply Agreement, the Commercial Supply Agreement, and for no other
purpose. The Existing Materials shall be made available to AstraZeneca for such use free of charge. To the extent that any Supplied Product is manufactured using Existing Materials, [***]. 

 

	4.	 PURCHASE ORDERS 

 

	4.1.	 Purchase Orders. No more than ten (10) business days after the Parties have agreed on the
first Clinical Supply Plan pursuant to Clause 3.1(a), SPINCO shall deliver to AstraZeneca a written purchase order in accordance with the Clinical Supply Plan, which states the quantity, the requested date for delivery in the applicable month, and
the Delivery Location (“Purchase Order”) in respect of the Firm Order set forth in such first Clinical Supply Plan. Thereafter, at least twelve (12) months prior to the requested date for delivery, SPINCO shall deliver to
AstraZeneca a Purchase Order in respect of each Firm Order for which SPINCO has not previously submitted a Purchase Order. 

  

	4.2.	 AstraZeneca’s Fulfillment of Purchase Orders. Subject to Clauses 4.1, 4.3 and 4.4,
AstraZeneca shall satisfy accepted Purchase Orders in accordance with their terms. For a given Purchase Order, AstraZeneca shall promptly notify SPINCO in writing if it becomes aware or believes that it will not be able to satisfy a particular
Purchase Order on time, in full or at all, which notice shall include an explanation in reasonable detail of the reason for AstraZeneca’s failure to comply with a particular Purchase Order and its proposed course of action for remedying such
failure. 

  

	4.3.	 Purchase Order Acceptance and Confirmation. AstraZeneca will accept each Purchase Order that
conforms to the relevant Firm Order, in writing, as soon as possible after receipt of the Purchase Order and in any event within ten (10) business days after its receipt. If AstraZeneca does not expressly reject such a Purchase Order, it will
be deemed accepted. SPINCO shall not submit any Purchase Order for quantities of Supplied Products in excess of the Firm Order or amend the quantities included in the Clinical Supply Plan by more than the permitted Modified Amount without
AstraZeneca’s prior written consent. If AstraZeneca consents to any such increase in quantities of Supplied Product (an “Additional Quantity”) it shall use Commercially Reasonable Efforts to deliver such Additional Quantity.
Where AstraZeneca accepts the Purchase Order, such confirmation will include the estimated delivery date; otherwise, for Purchase Orders deemed accepted, the delivery date will be one month after the delivery date for the prior Purchase Order issued
by SPINCO. All affirmatively accepted or deemed accepted Purchase Orders shall be binding upon AstraZeneca and SPINCO; provided that AstraZeneca shall have no liability for any failure to deliver any Additional Quantity. For clarity, AstraZeneca
shall not be required to accept any Purchase Order in excess of the Firm Order amount, or that does not conform to the requirements in terms of lead time or Minimum Order Size (or maximum order size) as may be set forth in the Clinical Supply Plan.

  

	4.4.	 Terms and Conditions. All contracts, including Purchase Orders, between the Parties for the
Manufacture and supply of any Supplied Product shall be on the terms and conditions set out in this Supply Agreement (and Clinical Quality Agreement). All other terms and conditions (including any terms and conditions which SPINCO purports to apply
under any Purchase Order, specification or other document attached to any order form) are hereby excluded. 

  
 12 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	4.5.	 Accuracy. SPINCO shall be responsible for ensuring that its Purchase Orders are accurate and
comply with the requirements of this Supply Agreement. 

  

	4.6.	 Suppliers. The Parties acknowledge and agree that AstraZeneca may use Third Party vendors in
connection with the Manufacture and supply of Supplied Products under this Supply Agreement. AstraZeneca remains fully liable for its obligations, and SPINCO’s rights, under this Supply Agreement with respect to any act, omission, or failure
under this Supply Agreement, and any applicable agreements AstraZeneca enters with such AZ Suppliers will not modify this obligation on AstraZeneca. 

  

	5.	 DELIVERY 

  

	5.1.	 Delivery. AstraZeneca shall deliver to SPINCO the Supplied Products ordered pursuant to a given
Purchase Order by the required delivery dates therefor[***] with the required Certificate(s) of Analysis for the Supplied Product(s). Unless otherwise agreed by the Parties, SPINCO shall arrange for its nominated carrier to be at the relevant
Delivery Location (ready for the relevant Supplied Product to be loaded on to SPINCO’s carrier) within two (2) business days of AstraZeneca giving it written notice that such Supplied Product is ready for loading. If for any reason SPINCO
fails to arrange for its carrier to collect such Supplied Product from the Delivery Location within this timeframe then delivery will be deemed to have occurred and AstraZeneca may, at its option either: (a) acting as agent for SPINCO and at
SPINCO’s cost and expense, arrange for a delivery company to collect such Supplied Products from the Delivery Location for delivery to any premises of SPINCO or (b) store the Supplied Products until SPINCO collects them and SPINCO shall be
liable for all related costs and expenses (including, storage and insurance), and for the avoidance of doubt, all risk of loss pursuant to Clause 6.1. 

  

	5.2.	 Delivery Date. AstraZeneca shall deliver Supplied Products in accepted Purchase Orders within
five (5) business days of the agreed delivery date and shall provide notice to SPINCO if AstraZeneca’s date of shipment to the carrier is early or delayed. However, such date is intended to be an estimate only and time shall not be made of
the essence by notice. AstraZeneca shall not be liable for any delay in delivery of the Supplied Products that is caused by Force Majeure, or by SPINCO’s negligence or breach of this Supply Agreement in a manner that affects the delivery date,
or by SPINCO’s failure to promptly provide AstraZeneca with adequate delivery instructions for the Supplied Products. 

  

	5.3.	 Installments. AstraZeneca may deliver any Supplied Products or make them available for loading on to
SPINCO’s carrier (as applicable) by separate installments, provided SPINCO has given its consent to such installments (such consent not to be unreasonably withheld, delayed or conditioned). 

 

	5.4.	 Documentation. All deliveries must be accompanied by the documentation specified in Exhibit 1,
subject to any variations that are mutually agreed between the Parties to cater for the local requirements of the relevant countries where the Supplied Product will be used in clinical trials. 

 

	5.5.	 Quantity. In respect of all Purchase Orders, AstraZeneca shall be entitled to deliver quantities
of Supplied Products which are plus or minus ten percent (10%) of the quantity set out in the Purchase Order and SPINCO shall not be entitled to reject any delivery on this basis, provided that SPINCO shall only be required to pay for the quantity
of Supplied Products that is delivered. 

  
 13 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	5.6.	 Packaging. AstraZeneca shall package the Supplied Products in accordance with its customary
practices, unless otherwise specified in writing by SPINCO, including its customary primary packaging and an appropriate shipping container, or such other containers or packaging as the Parties may agree from time to time, and prior to shipment,
AstraZeneca shall perform or have a Third Party perform release testing for the Supplied Product pursuant to the applicable Specification, cGMP, and the Clinical Quality Agreement. AstraZeneca shall label the Supplied Products only as necessary to
identify the content of the container in which the respective Supplied Product is supplied to SPINCO. SPINCO is otherwise responsible for Labelling and packaging the Supplied Products for its clinical trials. 

 

	5.7.	 Shipping/Insurance. If mutually agreed, AstraZeneca shall ship the Supplied Products from the
Delivery Location to a delivery location requested by SPINCO fully insured, using a delivery company reasonably acceptable to SPINCO. The associated costs (e.g., shipping, freight, handling, insurance, and duties) shall be charged to SPINCO and
separately listed, at cost, on the invoice associated with the Supplied Products. 

  

	6.	 RISK AND TITLE 

 

	6.1.	 Risk and Title. Title to and risk of loss of Supplied Product purchased by SPINCO shall pass to
SPINCO on delivery or deemed delivery at the Delivery Location. 

  

	7.	 PRICE 

  

	7.1.	 Price of Supplied Products. The price payable by SPINCO for each unit of each SKU of Supplied
Product shall be[***] (the “Supply Price”). 

  

	7.2.	 Supply Price Changes. AstraZeneca shall, no later than at the end of the fourth quarter of each
Calendar Year, provide to SPINCO the estimated Supply Price with respect to Firm Orders for Supplied Products to be supplied by AstraZeneca during the next Calendar Year, including assumptions relating to inflation and currency fluctuations. If
requested by SPINCO, no more than once annually, the Parties shall meet to discuss and consult on the estimate of the Supply Price. The Supply Price initially payable for Supplied Products delivered in the next Calendar Year shall be increased or
decreased in accordance with the updated estimate performed by AstraZeneca pursuant to this Clause 7.2 and the actual Supply Price shall be calculated and any adjustment made at the end of such Calendar Year in accordance with Clause 7.3.

  

	7.3.	 Reporting [***]; True-Up. AstraZeneca shall, no
later than at the end of the first quarter of each Calendar Year, provide SPINCO with a calculation of the Supply Price relating to the Supplied Products delivered in the preceding Calendar Year. If requested by SPINCO, no more than once annually,
the Parties shall meet to discuss and consult on the calculation [***]. [***] Any payment pursuant to this Clause 7.3 (a “True-Up Payment”) shall be made within [***] from the date AstraZeneca
provides the calculation pursuant to this Clause 7.3 to SPINCO. 

  

	7.4.	 Services Fees. In consideration for the performance of the Services by AstraZeneca, SPINCO shall
pay the fees set forth in the applicable Services Schedule (the “Services Fees”); provided that, where Services are to be charged on a time basis, unless otherwise agreed, the Services Fees shall be based on the FTE Rate.
AstraZeneca shall also be reimbursed for any Out-of-Pocket Costs; [***] 

  

	7.5.	 Currency. All amounts to be paid by SPINCO and AstraZeneca under this Supply Agreement shall be
payable in US Dollars. 

  
 14 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	7.6.	 Financial Records. AstraZeneca shall, and shall cause its Affiliates to, keep complete and
accurate financial books and records pertaining to the Manufacturing of Supplied Products, including [***], in sufficient detail to calculate and verify all amounts payable under this Supply Agreement. AstraZeneca shall, and shall cause its
Affiliates to, retain such books and records until the later of (a) three (3) years after the end of the period to which such books and records pertain and (b) such period as may be required by Applicable Law. 

 

	7.7.	 Financial Audits. At the request of SPINCO, and no more frequently than once per Calendar Year,
AstraZeneca shall, and shall cause its Affiliates to, permit an independent auditor designated by SPINCO and reasonably acceptable to AstraZeneca, at reasonable times and upon reasonable notice, to audit the books and records maintained pursuant to
Clause 7.6 solely to ensure the accuracy of the calculation of [***] Supply Price hereunder. Any such independent auditor shall be under confidentiality obligations at least as restrictive as those set forth between the Parties with respect to
Confidential Information disclosed by one Party to the other. The cost and expense of such audit shall be borne by SPINCO, unless the audit reveals, with respect to a Calendar Year, a variance of more than [***] calculated by AstraZeneca pursuant to
Clause 7.3 for such period, in which case AstraZeneca shall bear the cost and expense of the audit; provided, however, that the cost and expense of the first audit conducted with respect to the calculation of [***] component of the Supply Price
shall be borne equally by the Parties. Unless disputed pursuant to Clause 7.8, if any audit concludes that a True-Up Payment is owed by AstraZeneca or SPINCO pursuant to Clause 7.3, the Party owing such True-Up Payment shall pay such True-Up Payment with interest from the date originally due in accordance with the interest rate set out in Clause 8.3. 

 

	7.8.	 Audit Dispute. In the event of a dispute with respect to any audit under Clause 7.7, AstraZeneca
and SPINCO shall work in good faith to resolve the disagreement. If the Parties are unable to reach a mutually acceptable resolution of any such dispute within [***], the dispute shall be submitted for resolution to an independent registered public
accounting firm jointly selected by each Party’s independent registered public accountants or to such other Person as the Parties shall mutually agree (the “Auditor”). The decision of the Auditor shall be final and the costs of
such proceeding as well as the initial audit shall be borne between the Parties in such manner as the Auditor shall determine. Not later than [***] after such decision and in accordance with such decision, the Party owing a True-Up Payment shall pay such True-Up Payment, with interest from the date originally due in accordance with the interest rate set out in Clause 8.3. 

 

	8.	 INVOICING AND PAYMENT 

 

	8.1.	 Invoicing. All orders under this Supply Agreement shall be invoiced at the time of delivery to
the Delivery Location, or if applicable under Clause 5.7, at the time of shipment. Any other costs, expenses or other sums which may be chargeable by AstraZeneca under this Supply Agreement, including Services Fees and
Out-of-Pocket Costs, shall be invoiced by AstraZeneca in arrears, on a monthly or a less frequent basis as AstraZeneca may (in its sole discretion) decide. AstraZeneca
will provide SPINCO with a reasonable level of supporting documentation for such amounts, and, if requested by SPINCO, any additional documentation reasonably required to obtain any tax-related deductions. 

 

	8.2.	 Payment. SPINCO shall pay each invoice submitted under this Supply Agreement within [***] after
SPINCO’s receipt of the invoice. The amounts payable by SPINCO to AstraZeneca pursuant to this Agreement (“Payments”) shall not be reduced on account of any Taxes unless required by Applicable Law. AstraZeneca alone shall be
responsible for paying any and all Taxes (other than withholding Taxes required to be paid by SPINCO) levied on account of, or measured in whole or in part by reference to, any Payments it receives. SPINCO shall deduct or withhold from the Payments
any Taxes that it is required 

  
 15 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
by Applicable Law to deduct or withhold. To the extent that any such Tax is deducted or withheld, such amount shall be treated for all purposes of the Agreement as having been paid to the Person
in respect of which such deduction or withholding was made. Notwithstanding the foregoing, if AstraZeneca is entitled under any applicable Tax treaty to a reduction of rate of, or the elimination of, or recovery of, applicable withholding Tax, it
shall deliver to SPINCO or the appropriate Governmental Authority (with the assistance of SPINCO to the extent that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of
withholding or to relieve SPINCO of its obligation to withhold Tax, and SPINCO shall apply the reduced rate of withholding, or dispense with the withholding, as the case may be, to the extent it complies with the applicable Tax treaty. If, in
accordance with the foregoing, SPINCO withholds any amount, it shall make timely payment to the proper Governmental Authority of the withheld amount, and send to AstraZeneca proof of such payment within [***] following that payment. All Payments are
stated exclusive of Indirect Taxes. If any Indirect Taxes are chargeable in respect of any Payments, SPINCO shall pay such Indirect Taxes at the applicable rate in respect of any such Payments following the receipt, where applicable, of an Indirect
Taxes invoice in the appropriate form issued by AstraZeneca in respect of such Payments, such Indirect Taxes to be payable on the due date of the payment of the Payments to which such Indirect Taxes relate. AstraZeneca shall issue its invoices for
all amounts payable under this Agreement consistent with Indirect Tax requirements and irrespective of whether the sums may be netted for settlement purposes. 

  

	8.3.	 Failure to Timely Pay. If a Party fails to pay any amount payable under this Supply Agreement by
the due date for payment, then: 

  

	 	(a)	 interest shall accrue on that amount for the period beginning on the due date for payment and ending on
the date of actual payment (both before and after judgment) at the rate of [***] [***]. Interest shall be calculated on the basis of [***]; and 

  

	 	(b)	 if amounts are payable by SPINCO, without prejudice to Clause 8.3(a) and subject to giving SPINCO [***] prior
written notice of its intention to do so, AstraZeneca shall be entitled to suspend any of its obligations under this Supply Agreement until such time as any unpaid amounts have been paid in full. 

 

	9.	 REPRESENTATIONS AND WARRANTIES 

 

	9.1.	 Representations and Warranties. AstraZeneca and SPINCO each represents and warrants to the other
that: 

  

	 	(a)	 Duly Executed. This Supply Agreement has been duly executed and delivered by such Party and constitutes
a legal, valid and binding obligation of such Party, enforceable against such Party in accordance with its terms, except as such enforceability may be limited by applicable insolvency and other laws affecting creditors’ rights generally or by
the availability of equitable remedies. 

  

	 	(b)	 Duly Authorized; No Conflicts. The execution, delivery and performance of this Supply Agreement by such
Party and all instruments and documents to be delivered by such Party hereunder and the performance of such Party’s obligations hereunder: 

  

	 	(i)	 are within the corporate power of such Party; 

 

	 	(ii)	 have been duly authorized by all necessary or proper corporate action; 

 

	 	(iii)	 do not conflict with any provision of the charter documents of such Party; 

  
 16 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(iv)	 do not conflict with or violate any requirement of Applicable Laws; 

 

	 	(v)	 do not and will not conflict with, violate or breach or constitute a default or require any consent under, any
contractual obligations of such Party, except such consents as shall have been obtained prior to the Effective Date; and 

  

	 	(vi)	 do not and will not require any filing or registration with or the license, permit, consent, approval or
authorization of or any notice to any Regulatory Authority, except such as shall have been obtained prior to the Effective Date. 

  

	 	(c)	 Duly Organized. It: 

 

	 	(i)	 is a company duly organized, validly existing and in good standing under the laws of its jurisdiction of
incorporation; 

  

	 	(ii)	 is duly qualified as a corporation and in good standing under the laws of each jurisdiction where its ownership
or lease of property or the conduct of its business requires such qualification, where the failure to be so qualified would have a material adverse effect on its financial condition or its ability to perform its obligations hereunder;

  

	 	(iii)	 has the requisite corporate power and authority and the legal right to conduct its business as now conducted
and hereafter contemplated to be conducted; 

  

	 	(iv)	 has all necessary licenses, permits, consents, authorizations or approvals from or by, and has made all
necessary notices to, all Governmental Authorities having jurisdiction, to the extent required for such ownership and operation; and 

  

	 	(v)	 is in compliance with its organizational documents. 

 

	9.2.	 Warranty by AstraZeneca. AstraZeneca hereby represents, warrants and covenants to SPINCO that:

  

	 	(a)	 on delivery (or deemed delivery) the quality (purity, physical and chemical properties) of the Supplied
Products supplied by it to SPINCO shall be in accordance with their respective Specifications, all Applicable Laws (including cGMP), and the Clinical Quality Agreement, in all material respects. This warranty is exclusive and is in lieu of all other
warranties, whether written or oral, express, implied or statutory. EXCEPT WITH RESPECT TO THE FOREGOING WARRANTY, THERE IS NO WARRANTY OF MERCHANTABILITY, SATISFACTORY QUALITY OR OF FITNESS FOR A PARTICULAR PURPOSE OR OTHERWISE GIVEN BY ASTRAZENECA
WITH RESPECT TO SUPPLIED PRODUCTS; 

  

	 	(b)	 during the Supply Term it shall comply with all applicable regulations, statutes, or other Applicable Laws in
performance of this Supply Agreement; 

  

	 	(c)	 it is not debarred by any applicable Governmental Authority or Regulatory Authority as of the Effective Date,
and AstraZeneca has not and shall not knowingly use in any capacity the services of any Person who has been debarred by any applicable authority with respect to its performance of this Supply Agreement. AstraZeneca will immediately notify SPINCO in
the event that AstraZeneca becomes aware that it, its permitted subcontractors, or any of its or their employees engaged in the performance of this Supply Agreement becomes debarred during the Supply Term. 

  
 17 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	10.	 NON-CONFORMING PRODUCT AND SHORTFALLS 

 

	10.1.	 Conforming Products. AstraZeneca shall Manufacture, or have Manufactured, the Supplied Products
in accordance in all material respects with: 

  

	 	(a)	 the applicable Specification; 

 

	 	(b)	 the Clinical Quality Agreement; and 

 

	 	(c)	 all Applicable Laws (including cGMP) in the countries in which they are Manufactured. 

 

	10.2.	 Shortfall or Non-Conforming Product. SPINCO shall
promptly notify AstraZeneca of any Shortfall or Non-Conforming Product in any delivery of Supplied Products. In such event, SPINCO shall provide AstraZeneca with a detailed written report of the alleged
Shortfall or Non-Conformance no later than: 

  

	 	(a)	 [***] after SPINCO’s receipt of the applicable Supplied Product (or such different period of time
that may be set forth in the Clinical Quality Agreement with respect to a Non-Conformance), for any Shortfall or for any Non-Conformance that could be discovered within
the applicable period by SPINCO exercising reasonable diligence or its responsibilities under the Clinical Quality Agreement (“Apparent Defects”); or 

 

	 	(b)	 [***] after the Non-Conformance has become apparent, but in any
event no later than the actual date of expiry of the shelf-life of the Supplied Product in question (or such different period of time that may be set forth in the Clinical Quality Agreement), for any
Non-Conformance which is not an Apparent Defect (“Latent Defects”). 

  

	10.3.	 Remedies for Shortfall or Non-Conformance. Subject to
Clause 10.5, provided SPINCO has duly notified AstraZeneca of a Shortfall or a Non-Conforming Product in accordance with Clause 10.2, AstraZeneca shall at SPINCO’s option either: 

 

	 	(a)	 in the case of any Shortfall: 

 

	 	(i)	 make up the Shortfall as soon as reasonably practicable, at AstraZeneca’s cost and expense (including if
reasonably required express shipping costs); or 

  

	 	(ii)	 refund to SPINCO the proportion of the Supply Price paid by SPINCO which equates to the amount of the Shortfall
(including shipping costs), or, if the invoice has not been paid, cancel the invoice and issue a new invoice for the actual amount of the Supplied Product delivered; 

 

	 	(b)	 in the case of any Non-Conforming Product: 

 

	 	(i)	 replace the Non-Conforming Product (or relevant portion of the
Non-Conforming Product) as soon as reasonably practicable given the nature of the non-conformance, at AstraZeneca’s cost and expense (including if reasonably
required express shipping costs); or 

  

	 	(ii)	 refund to SPINCO the Supply Price paid to AstraZeneca by SPINCO for the
Non-Conforming Product (including shipping costs), or, if the invoice has not been paid, cancel the invoice. 

  
 18 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	10.4.	 Return or Destruction of Non-Conforming Products. SPINCO
may reject any Non-Conforming Product by providing notice of rejection to AstraZeneca, giving its reasons for rejection and reasonable evidence for the Non-Conformance.
SPINCO shall, at AstraZeneca’s option and expense (including shipping costs), return to AstraZeneca or destroy in an environmentally acceptable manner, in accordance with Applicable Law (and certify destruction of) any Non-Conforming Product. 

  

	10.5.	 Disagreement. If a dispute arises between the Parties as to whether or not a Supplied Product is
a Non-Conforming Product, which cannot be resolved by the Parties within [***] of a claim being notified by SPINCO to AstraZeneca, either Party may require that the matter in dispute be referred to an
independent testing laboratory or other appropriate independent expert mutually agreed upon by the Parties or, failing agreement, appointed by the ICC International Centre for Expertise at the request of either Party (the “Independent
Expert”). 

  

	10.6.	 Referral to Independent Expert. The referral of any matter to the Independent Expert pursuant to
Clause 10.5 shall be solely for the purpose of establishing whether or not there has been a supply of Non-Conforming Product. Except in the case of fraud or manifest error on the part of the Independent
Expert, the decision of the Independent Expert will be final and binding upon the Parties. If the Independent Expert decides that the relevant Product is a Non-Conforming Product, the costs of the Independent
Expert will be borne by AstraZeneca. In all other circumstances, the costs of the Independent Expert will be borne by SPINCO. 

  

	11.	 REGULATORY MATTERS 

 

	11.1.	 Clinical Quality Agreement. Within [***] of the Effective Date, the Parties will enter into the
Clinical Quality Agreement. AstraZeneca and SPINCO shall perform their respective obligations and comply with all provisions of the Clinical Quality Agreement. AstraZeneca shall not be required to commence the Manufacture of Supplied Products
hereunder until execution of the Clinical Quality Agreement. 

  

	11.2.	 Adverse Event Reporting. The reporting of adverse events in relation to any Supplied Product
supplied to SPINCO under this Supply Agreement will be governed by the Pharmacovigilance Agreement to be mutually agreed and executed by the Parties. 

  

	11.3.	 Recalls. 

 

	 	(a)	 Recalls of Supplied Products will be governed by the Clinical Quality Agreement. 

 

	 	(b)	 SPINCO shall be responsible for all costs and expenses of each recall (whether requested by SPINCO or
AstraZeneca), including costs and expenses incurred by AstraZeneca, except, subject to Clause 15.3, to the extent such recall results from the failure of AstraZeneca to deliver Supplied Product that complies with the applicable Specification, the
Clinical Quality Agreement, or any Applicable Laws (including cGMP), at the time of delivery to the Delivery Location. Subject to Clause 15.3, AstraZeneca shall be responsible for all costs and expenses of each recall (whether requested by SPINCO or
AstraZeneca), including costs and expenses incurred by SPINCO, and AstraZeneca shall fully reimburse SPINCO the Supply Price for each unit of recalled Supplied Product, to the extent such recall results from the failure of AstraZeneca to deliver
Supplied Product that complies with the applicable Specifications, the Clinical Quality Agreement, or any Applicable Laws (including cGMP), at the time of delivery to the Delivery Location. 

 

	 	(c)	 If there is any dispute concerning which Party’s acts or omissions gave rise to any recall of Supplied
Product, such dispute shall be referred for decision to an Independent Expert. The decision of such Independent Expert shall be in writing and, except for manifest error on the face of the decision, shall be binding on both SPINCO and AstraZeneca.
The costs of such Independent Expert shall be borne by 

  
 19 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
the Party that is found to be responsible for the recall by the Independent Expert. After such determination, costs shall be paid by the responsible Party in accordance with Clause 11.3(b).

  

	 	(d)	 SPINCO shall keep complete and accurate records of the distribution of the Supplied Products, including methods
for tracking and traceability as required under Applicable Laws, to enable appropriate procedures to be implemented in the event that a voluntary or mandatory recall of any Supplied Product is required and AstraZeneca shall have rights to audit such
records. 

  

	12.	 COMPLIANCE 

  

	12.1.	 Compliance with Applicable Laws. In performing their respective obligations under this Supply
Agreement, each Party shall comply in all material respects with Applicable Laws. 

  

	12.2.	 Anti-Corruption Laws. Without prejudice to Clause 12.1, each Party shall (and shall procure that
each of its Affiliates, and each of its and its Affiliates officers, directors, employees, agents, representatives, consultants and subcontractors who, in each case, are directly and effectively involved, if any, in the rendering of such
Party’s obligations under this Supply Agreement shall): 

  

	 	(a)	 ensure that the performance of such Party’s obligations under this Supply Agreement shall at all times
comply with applicable Anti-Corruption Laws; and 

  

	 	(b)	 not knowingly take any action that will, or would reasonably be expected to, cause the other Party or its
Affiliates to be in violation of any applicable Anti-Corruption Laws. 

  

	13.	 CONFIDENTIALITY AND INTELLECTUAL PROPERTY 

 

	13.1.	 Confidentiality. 

 

	 	(a)	 At all times during the Supply Term and, for a period of [***] following expiry or termination of this Supply
Agreement, each Party shall and shall cause its officers, directors, employees and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or indirectly, for any purpose, any Confidential Information
furnished or otherwise made known to it, directly or indirectly, by the other Party, except to the extent such disclosure or use is expressly permitted by the terms of this Supply Agreement; provided that with respect to any MedImmune Manufacturing
Technology, including CMC Data provided to SPINCO pursuant to Clause 13.8, if any, the foregoing confidentiality obligation shall survive indefinitely. “Confidential Information” means any technical, business or other information
provided by or on behalf of one Party to the other Party in connection with this Supply Agreement, whether prior to, on or after the Effective Date, including information relating to the terms and conditions of this Supply Agreement (subject to
Clause 13.3), information relating to the Supplied Products or Services, or the scientific, regulatory or business affairs or other activities of either Party. Notwithstanding the foregoing, the confidentiality and
non-use obligations under this Clause 13.1 with respect to any Confidential Information shall not include any information that: 

 

	 	(i)	 is or hereafter becomes part of the public domain by public use, publication, general knowledge or the like
through no breach of this Supply Agreement by the receiving Party (or its Affiliates or permitted representatives); 

  
 20 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(ii)	 can be demonstrated by documentation or other competent proof to have been in the receiving Party’s (or
its Affiliates’) possession prior to disclosure by the disclosing Party without any obligation of confidentiality with respect to such information; 

  

	 	(iii)	 is subsequently received by the receiving Party from a Third Party who is not bound by any obligation of
confidentiality with respect to such information; 

  

	 	(iv)	 has been published by a Third Party or otherwise enters the public domain through no fault of the receiving
Party in breach of this Supply Agreement; or 

  

	 	(v)	 can be demonstrated by documentation or other competent evidence to have been independently developed by or for
the receiving Party without reference to the disclosing Party’s Confidential Information. 

  

	 	(b)	 Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or
in the possession of the receiving Party merely because the Confidential Information is embraced by more general information in the public domain or in the possession of the receiving Party. Further, any combination of Confidential Information shall
not be considered in the public domain or in the possession of the receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the receiving Party unless the combination and
its principles are in the public domain or in the possession of the receiving Party. 

  

	 	(c)	 For clarity, (i) except to the extent assigned to SPINCO pursuant to the APA, Confidential Information of
AstraZeneca or its Affiliates known to employees of SPINCO prior to the Effective Date shall remain AstraZeneca Confidential Information and shall be deemed to have been disclosed to SPINCO subject to obligations of confidentiality; and
(ii) even if known to any such employee, SPINCO shall not use or disclose any MedImmune Manufacturing Technology except as provided in Clause 13.8. 

  

	13.2.	 Permitted Disclosure. Notwithstanding Clause 13.1, but in each case ((a) through (d)) subject to
Clause 13.8 (MedImmune Manufacturing Technology) and Clause 20.2 (Technology Transfer): 

  

	 	(a)	 each Party may disclose all or any part of the other Party’s Confidential Information to its Affiliates,
and to its and its Affiliates’ respective Personnel, financial and legal advisors, investors and suppliers (“Representatives”); provided, however, that such Party ensures that such Representatives comply mutatis mutandis
with the obligations imposed on such Party under this Clause 13 and such Party shall be liable for any breach of such obligations by its Representatives. Each Party will disclose Confidential Information received from the other Party only to those
of its Representatives who have a need to know such Confidential Information for the purpose carrying out its obligations or exercising its rights under this Supply Agreement or, with respect to disclosures to financial advisors and investors, as
provided in Clause 13.2(b), and in any case only to the extent required for the permitted purpose. For example, disclosure of expenses on a profit and loss basis would not require disclosure of the actual Supply Price, the terms of Clause 7.1 or any
details [***]; 

  
 21 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(b)	 SPINCO may disclose AstraZeneca’s Confidential Information to financial advisors and investors for the
purpose of raising finance for SPINCO (e.g. for clinical trials), provided that AstraZeneca has given its prior written consent to the form and content of such proposed disclosure (such consent not to be unreasonably withheld, delayed or
conditioned). Following approval of such disclosure document by AstraZeneca, subject to Clause 13.2(a), SPINCO may disclose the information contained in such document to financial advisors, investors and potential investors for such purpose without
the need for further approval by AstraZeneca; 

  

	 	(c)	 each Party may disclose the other Party’s Confidential Information to the extent that such disclosure is
(i) required to be made in response to a valid order of a court or governmental authority of competent jurisdiction; or (ii) is otherwise required by Applicable Law; provided that the Party requested or required to disclose such
Confidential Information shall first promptly notify the other Party in writing in a timely manner so that such other Party may seek a protective order or other appropriate remedy or, in such other Party’s sole discretion, waive compliance with
the confidentiality provisions of this Supply Agreement as to their own Confidential Information. Each Party will cooperate in all reasonable respects in connection with any reasonable actions to be taken for the foregoing purpose. In any event, the
Party requested or required to disclose such Confidential Information may furnish it as required by such valid court or governmental order or Applicable Law (subject to any such protective order or other appropriate remedy) without liability
hereunder; provided, that such Party furnishes only that portion of the Confidential Information which such Party is advised by an opinion of its counsel is legally required, and such Party exercises reasonable efforts to obtain reliable assurances
that a protective order or other comparable confidential treatment will be accorded such Confidential Information; and 

  

	 	(d)	 each Party may disclose the other Party’s Confidential Information to any Governmental Authority or
Regulatory Authority to the extent necessary to obtain the approval of any such Governmental Authority or Regulatory Authority to Manufacture and supply any Supplied Product or perform any Services pursuant to the terms and conditions of this Supply
Agreement; provided, however, that reasonable measures shall be taken to assure confidential treatment of such Confidential Information. 

  

	 	(e)	 For clarity, MedImmune Manufacturing Technology will only be disclosed to SPINCO in accordance with Clause 13.8
and, notwithstanding this Clause 13.2, shall only be disclosed by SPINCO as expressly permitted by Clause 13.8. 

  

	13.3.	 Press Releases; Public Announcements. Except as provided in the APA, SPINCO and AstraZeneca agree
not to issue any press releases or public announcements concerning this Supply Agreement (and to ensure that their respective Affiliates do not do so) without the prior written consent of the other Party to the form, timing and content of any such
release or announcement, except as required by Applicable Laws, including disclosure required by any securities exchange.  

  

	13.4.	 Injunctive Relief. Each Party acknowledges that damages resulting from disclosure of Confidential
Information not permitted hereby may be an insufficient remedy and that in the event of any such disclosure or any indication of an intent to disclose such information, the other Party shall be entitled to seek, by way of private litigation,
injunctive relief or other equitable relief in addition to any and all remedies available at law or in equity. 

  

	13.5.	 Return or Destruction of Confidential Information. Subject to Clause 13.6, on expiry or
termination of this Supply Agreement except as provided to SPINCO under Clause 20.2 (Technology Transfer) and subject to an on-going license, or at any time at the disclosing Party’s request, the
receiving Party shall return to the disclosing Party all copies containing 

  
 22 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
Confidential Information of the disclosing Party or, at the disclosing Party’s option, destroy all copies of such Confidential Information. The return or destruction of the Confidential
Information of the disclosing Party will not affect the receiving Party’s obligation to observe the confidentiality and non-use restrictions in respect of that Confidential Information set out in this
Supply Agreement. 

  

	13.6.	 Permitted Retention of Confidential Information. Each Party may keep one (1) copy of
Confidential Information for evidence purposes at a secure place subject to the confidentiality and non-use obligations provided in this Clause 13. The aforementioned return and destruction obligation shall
not apply to electronic copies of Confidential Information which are rightfully contained in computers, word processors, communication systems and system-backup media (collectively “IT Media”) which do not need to be destroyed or
returned, provided that such IT Media are: (a) overwritten in the ordinary course of their reuse; or (b) at all times maintained in confidence and not readily accessible and the receiving Party shall treat such copies as confidential in
accordance with this Clause 13. 

  

	13.7.	 Intellectual Property. 

 

	 	(a)	 Intellectual Property Rights arising in connection with the activities undertaken pursuant to this Supply
Agreement (“Arising IPR”) shall be owned according to inventorship; provided that to the extent that any Arising IPR conceived, developed or generated by AstraZeneca or an Affiliate of AstraZeneca relates exclusively to the Product,
such Arising IPR will be owned by SPINCO (“New SPINCO IPR”). AstraZeneca shall promptly disclose to SPINCO all Know-How that relates exclusively to the Product, and SPINCO shall have the sole
discretion in pursuing Patents or other intellectual property rights protection for such Know-How. AstraZeneca hereby assigns to SPINCO all right, title and interest of AstraZeneca in any New SPINCO IPR.

  

	 	(b)	 All Background IPR of AstraZeneca or its Affiliates shall remain vested in and the exclusive property of
AstraZeneca, its Affiliates or its licensors, as applicable. With the exception of New SPINCO IPR, all Arising IPR conceived, developed or generated by AstraZeneca or an Affiliate of AstraZeneca will be owned by AstraZeneca. 

 

	 	(c)	 SPINCO, on behalf of itself or its Affiliates, hereby grants to AstraZeneca and its Affiliates a worldwide, non-exclusive, royalty-free, non-transferable license and a right of reference and use under SPINCO IP, with the right to grant further licenses and sublicenses or rights of
reference and use to any Affiliate, AZ Supplier or subcontractor, to the extent necessary during the Supply Term for AstraZeneca and its Affiliates to perform their obligations hereunder. 

 

	13.8.	 MedImmune Manufacturing Technology. Notwithstanding anything in this Supply Agreement to the
contrary, in no event shall AstraZeneca be obligated to disclose any MedImmune Manufacturing Technology to SPINCO, except as provided in this Clause 13.8. During the Supply Term, upon SPINCO’s reasonable request, and at SPINCO’s sole cost
and expense, AstraZeneca shall provide SPINCO one or more letters providing SPINCO a right of reference to the relevant IND or other relevant filing with a Regulatory Authority, or shall otherwise provide SPINCO via such other methods as may be
available, to allow SPINCO to reference with the applicable Regulatory Authority the relevant CMC Data for the Product solely to the extent necessary for SPINCO to obtain or maintain an IND or other Regulatory Approval for the Product. Such other
methods may entail AstraZeneca providing such CMC Data directly to such Regulatory Authority (to the extent permitted by Applicable Law) or, at AstraZeneca’s sole election, directly to SPINCO; provided that SPINCO shall permit AstraZeneca to
seek any and all measures available to protect the confidentiality of and 

  
 23 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
AstraZeneca’s interests in and to such CMC Data, including, if such information is provided directly to SPINCO, restricting access to such CMC Data through a secure data room or portal to
specified members of SPINCO’s regulatory affairs and quality assurance departments who need to know such CMC Data in order to prepare, submit, obtain, or maintain an IND or BLA or Regulatory Approval for the Product and who have entered into
confidentiality agreements with AstraZeneca in a form reasonably acceptable to AstraZeneca, and SPINCO shall provide full cooperation and assistance to AstraZeneca in seeking to obtain such protection. If required by AstraZeneca, the cover letter
for any IND or other Regulatory Approval application submitted by SPINCO in connection with this Supply Agreement shall instruct the applicable Regulatory Authority to direct any questions with respect to the CMC Data for the Product directly to
AstraZeneca. If, in connection with obtaining or maintaining any IND or other Regulatory Approval for the Product, SPINCO receives any question from a Regulatory Authority with respect to the CMC Data for the Product or otherwise in connection with
any MedImmune Manufacturing Technology, unless AstraZeneca has specified otherwise, SPINCO shall not answer any such question and shall promptly forward such question to AstraZeneca and unless AstraZeneca has specified otherwise, AstraZeneca shall,
where this is permissible, provide the answer to any such question directly to the applicable Regulatory Authority. For clarity, (i) if AstraZeneca provides a right of reference, or such other method for SPINCO to utilize the CMC Data other
than providing such CMC Data directly to specified personnel at SPINCO, such reference or other method shall not entitle SPINCO to view, access, or otherwise obtain such CMC Data or any other MedImmune Manufacturing Technology; and (ii) to the
extent that MedImmune Manufacturing Technology is disclosed pursuant to this Clause 13.8, it may not be further disclosed within SPINCO, to an Affiliate or to any Third Party except to: 

 

	 	(a)	 a Regulatory Authority pursuant to this Clause 13.8 to the extent necessary to obtain or maintain a Regulatory
Approval for the Product; provided, however, that reasonable measures shall be taken to assure confidential treatment of such MedImmune Manufacturing Technology and SPINCO shall not disclose any MedImmune Manufacturing Technology to any Regulatory
Authority or answer any query raised by a Regulatory Authority with respect to MedImmune Manufacturing Technology, unless SPINCO has provided a copy of the query (or other explanation of the need to disclose) and proposed disclosure or response to
AstraZeneca and AstraZeneca has given its written consent to such proposed disclosure or response (such consent not to be unreasonably withheld, conditioned, or delayed); or 

 

	 	(b)	 the extent required pursuant to Clause 13.2(c), as provided therein. 

 

	 	(C)	 NOTWITHSTANDING ANY OTHER PROVISION IN THIS SUPPLY AGREEMENT, EXCEPT AS EXPRESSLY PROVIDED IN THIS CLAUSE 13.8,
SPINCO SHALL NOT USE OR DISCLOSE MEDIMMUNE MANUFACTURING TECHNOLOGY FOR ANY PURPOSE. 

  

	14.	 SPECIAL EQUIPMENT 

 

	14.1.	 Purchase of Special Equipment. SPINCO shall provide or pay the cost of Special Equipment, and pay
the costs of installation and validation of such Special Equipment, as described below. AstraZeneca shall advise SPINCO of any Special Equipment requirements and the estimated costs associated with the purchase, installation and qualification of
such Special Equipment. If the cost of purchase of such Special Equipment is for an amount greater than [***] for any single item, the Parties must mutually agree on such Special Equipment and SPINCO shall either purchase such Special Equipment and
furnish it to AstraZeneca. In any case in which SPINCO furnishes Special Equipment to AstraZeneca, AstraZeneca shall install and qualify such Special Equipment (or arrange for such installation and qualification) at

  
 24 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
SPINCO’s cost. If the cost of purchase of such Special Equipment is for an amount less than [***] for any single item, AstraZeneca shall purchase such Special Equipment at SPINCO’s
direction and supervision and promptly bill SPINCO for all amounts AstraZeneca owes for such Special Equipment. AstraZeneca shall also bill SPINCO for the reasonable installation and equipment qualification costs after AstraZeneca installs the
Special Equipment. All Special Equipment shall remain at AstraZeneca’s Manufacturing facility. 

  

	14.2.	 Ownership of Special Equipment. SPINCO shall own any Special Equipment upon the date it makes
full payment to AstraZeneca for said Special Equipment. Thereafter, title to and risk of loss of all Special Equipment shall be retained by SPINCO, even if such Special Equipment resides at an AstraZeneca facility; provided, however, that
AstraZeneca shall be responsible for replacing any SPINCO owned Special Equipment that is destroyed due to AstraZeneca’s negligence or misconduct. 

  

	14.3.	 Maintenance of Special Equipment. AstraZeneca shall be responsible for routine maintenance and
servicing of the Special Equipment. SPINCO shall be responsible for the cost of non-routine maintenance and servicing of the Special Equipment (including major repairs and material parts replacement), except
to the extent caused by AstraZeneca’s negligence or misconduct in which case AstraZeneca shall be responsible. To the extent commercially reasonable, AstraZeneca shall notify SPINCO prior to the performance of any
non-routine maintenance or servicing of the Special Equipment. SPINCO shall reimburse AstraZeneca at cost for such non-routine maintenance or servicing costs.

  

	14.4.	 Exclusive Use. Special Equipment shall be used exclusively for Manufacturing and supply
activities under this Supply Agreement, unless otherwise permitted by SPINCO. If SPINCO authorizes the use of the Special Equipment for other products, AstraZeneca and SPINCO shall mutually agree upon a credit in the reasonable amount of prorated
cost(s) of the Special Equipment (based on relative time of usage for each product). 

  

	15.	 INDEMNITIES 

  

	15.1.	 Indemnification of AstraZeneca. SPINCO shall indemnify and hold AstraZeneca and its
Affiliates harmless from and against any and all Losses arising from any claims from Third Parties (each a “Third Party Claim”) based on or deriving from AstraZeneca or its Affiliates’ Manufacturing a Supplied Product
for, or supplying such Supplied Product to, SPINCO or performing other services pursuant to this Supply Agreement, except to the extent that any such Third Party Claim or Losses result from a breach of this Supply Agreement by AstraZeneca or any of
its Affiliates or any of their respective Personnel.  

  

	15.2.	 Indemnification of SPINCO. Subject to Clause 15.3, AstraZeneca shall indemnify and hold SPINCO
and its Affiliates harmless from and against all Losses arising from Third Party Claims involving actual or alleged death or personal injury arising out of any defect or fault in Manufacture of, or Materials used in (other than Materials provided by
SPINCO), the Supplied Products to the extent that such Losses result from a breach of this Supply Agreement by AstraZeneca or any of its Affiliates or any of their respective Personnel. 

 

	15.3.	 Exceptions and Limitations on Indemnification and Recalls. AstraZeneca shall not be liable under
the indemnity in Clause 15.2 or pursuant to Clause 11.3(b), where the liability arises as a result of: 

  

	 	(a)	 the supply by SPINCO, its Affiliates or their respective Personnel or licensees of any Supplied Product which
has Apparent Defects, or whose shelf-life has expired; or 

  
 25 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(b)	 any defect or fault in any Supplied Product which is caused by any act or omission of SPINCO, its Affiliates or
by their respective Personnel or licensees, or by any damage or event occurring after delivery or deemed delivery to SPINCO. 

  

	15.4.	 Indemnification Procedures. As soon as either Party (the “Indemnitee”) becomes
aware of any matter which may result in making a claim under the indemnity against the other Party (the “Indemnifying Party”) in Clause 15.1 or Clause 15.2, the Indemnitee shall:  

 

	 	(a)	 give the Indemnifying Party notice of such matter as soon as reasonably practicable on becoming aware of
it; 

  

	 	(b)	 not at any time admit liability or otherwise settle or compromise, or attempt to settle or compromise, the
matter (or any aspect of it) except on the Indemnifying Party’s express written instructions; 

  

	 	(c)	 give the Indemnifying Party sole conduct of the defense, negotiation or settlement of any such matter upon
request; 

  

	 	(d)	 act in accordance with the Indemnifying Party’s reasonable instructions, and give the Indemnifying Party
such assistance as it may reasonably require in the conduct of any such defense, negotiation or settlement; and 

  

	 	(e)	 take all reasonable steps to mitigate any Losses which it may incur as a result of such matter.

  

	16.	 LIABILITY 

  

	16.1.	 Disclaimer. Except to the extent set out expressly in this Supply Agreement, all conditions,
warranties or other terms which might have effect between the Parties or be implied or incorporated into this Supply Agreement (whether by statute, common law or otherwise) are hereby excluded to the fullest extent permitted by Applicable Laws.
Without prejudice to the general nature of the previous sentence, unless this Supply Agreement specifically states otherwise, AstraZeneca does not make any representations or warranties with respect to any Supplied Product pursuant to this Supply
Agreement, including any representations or warranties as to non-infringement or fitness for a particular purpose. 

  

	16.2.	 Limitation of Liability. TO THE EXTENT PERMITTED BY LAW, NOTWITHSTANDING ANY OTHER PROVISION
CONTAINED HEREIN, UNLESS RESULTING FROM A PARTY’S WILLFUL MISCONDUCT, GROSS NEGLIGENCE, OR FRAUD, IN NO EVENT SHALL ASTRAZENECA, ON THE ONE HAND, OR SPINCO, ON THE OTHER HAND, BE LIABLE TO THE OTHER OR ANY OF THE OTHER’S AFFILIATES FOR ANY
CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR EXEMPLARY DAMAGES (INCLUDING LOST PROFITS, BUSINESS OR GOODWILL) SUFFERED OR INCURRED BY SUCH OTHER PARTY OR ITS AFFILIATES IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS SUPPLY
AGREEMENT. 

  

	16.3.	 Maximum Liability. THE AGGREGATE LIABILITY OF ASTRAZENECA UNDER OR IN CONNECTION WITH THIS SUPPLY
AGREEMENT SHALL NOT EXCEED [***] PROVIDED THAT SUCH LIMITATION SHALL NOT APPLY TO ASTRAZENECA’S OBLIGATION TO INDEMNIFY SPINCO PURSUANT TO CLAUSE 15.2 (INDEMNIFICATION) TO THE EXTENT SUCH THIRD PARTY CLAIM RESULTS FROM ASTRAZENECA’S GROSS
NEGLIGENCE OR WILLFUL MISCONDUCT. 

  
 26 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	16.4.	 Recovery of Damages. Neither Party shall be entitled under any provision of this Supply Agreement
to recover damages, or obtain payment, reimbursement, restitution or indemnity more than once in respect of the same loss, shortfall, damage, deficiency, breach or other event or circumstance. 

 

	17.	 INSURANCE 

  

	17.1.	 Insurance. Each Party shall, and shall ensure that their respective Affiliates shall, take out
and maintain such types and amounts of liability insurance or, in the case of AstraZeneca, self-insurance to cover liabilities related to its activities under this Supply Agreement as is normal and customary in the pharmaceutical industry generally
for Persons similarly situated, and shall upon request provide to the other Party evidence of such insurance coverage. Such insurance coverage shall remain in effect throughout the Supply Term and for a period of [***] thereafter.

  

	18.	 FORCE MAJEURE 

 

	18.1.	 Force Majeure. If a Party is prevented from or delayed in performing any of its obligations under
this Supply Agreement by a Force Majeure event then: 

  

	 	(a)	 the relevant obligations under this Supply Agreement shall be suspended for as long as the Force Majeure event
continues, and the Party shall not be in breach of this Supply Agreement or otherwise liable for any such failure or delay in the performance of such obligations during such event; 

 

	 	(b)	 as soon as reasonably practicable after the start of the Force Majeure event, the Party shall notify the other
of the nature of the Force Majeure event and the likely effects of the Force Majeure event on its ability to perform its obligations under this Supply Agreement; and 

 

	 	(c)	 as soon as reasonably practicable after the end of the Force Majeure event, it shall notify the other Party
that the Force Majeure event has ended, and shall resume performance of its obligations under this Supply Agreement. 

  

	18.2.	 If there is a Force Majeure event that AstraZeneca reasonably expects will prevent it from delivering at
least [***] Purchase Orders for more than [***] AstraZeneca shall prepare and present to SPINCO for discussion a summary remediation plan intended to address the supply situation as soon as commercially reasonable (the “Remediation
Plan”) and AstraZeneca shall consider in good faith SPINCO’s comments and suggestions. AstraZeneca shall use Commercially Reasonable Efforts to implement the Remediation Plan and shall provide SPINCO updates on a monthly basis on the
implementation and corrective effect of the Remediation Plan. 

  

	19.	 TERM AND TERMINATION 

 

	19.1.	 Term. This Supply Agreement commences and takes effect on the Effective Date and shall continue
in effect until the fifth (5th) anniversary of the Effective Date, unless and to the extent terminated earlier in accordance with the provisions of Clause 19.2 (the “Initial Term”). After the expiration of the Initial Term, this
Supply Agreement shall be automatically renewed for separate but successive one-year terms unless either Party provides written notice to the other Party that it does not intend to renew this Supply Agreement
at least twelve (12) months in advance of the end of the then-current term. The Initial Term and all such renewal terms together are referred to as the “Supply Term.” 

  
 27 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	19.2.	 Early Termination. This Supply Agreement may be terminated prior to the expiration of the Supply
Term as follows: 

  

	 	(a)	 Mutual Agreement. This Supply Agreement may be terminated upon the mutual written consent of AstraZeneca
and SPINCO at any time. 

  

	 	(b)	 Termination for Material Breach. In the event that either Party (the “Breaching Party”)
breaches any of its material obligations under this Supply Agreement, in addition to any other right and remedy the other Party (the “Complaining Party”) may have, the Complaining Party may terminate this Supply Agreement upon sixty
(60) days’ prior written notice (such sixty (60)-day period, the “Notice Period”) to the Breaching Party, specifying the breach and its claim of right to terminate; provided, however,
that the termination of this Supply Agreement shall not become effective at the end of the Notice Period if (i) the Breaching Party cures such breach during the Notice Period and notifies the Complaining Party of such cure, or (ii) such
breach cannot be cured during the Notice Period and the Breaching Party commences and diligently pursues actions to cure such breach within the Notice Period, and notifies Complaining Party of the same, in which case the Breaching Party shall have
an additional [***] period to cure such breach before such termination becomes automatically effective. 

  

	 	(c)	 Termination for Insolvency. Either Party may terminate this Supply Agreement immediately upon written
notice to the other Party if the other Party: (i) files in any court or with any Governmental Authority, pursuant to any statute or regulation of any state or country, a petition in bankruptcy or insolvency or for reorganization or for an
arrangement or for the appointment of a receiver or trustee of that Party or of its assets; (ii) proposes a written agreement of composition or extension of its debts; (iii) is served with an involuntary petition against it, filed in any
insolvency proceeding, and such petition is not dismissed within sixty (60) days after the filing thereof; (iv) consents to the appointment or taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator (or
similar official) of such Party or for any substantial part of its property or makes any assignment for the benefit of creditors; (v) admits in writing its inability to pay its debts generally as they become due; or (vi) has issued or
levied against its property any judgment, writ, warrant of attachment or execution or similar process that represents a substantial portion of its property. 

  

	 	(d)	 Termination for Convenience. AstraZeneca may terminate this Supply Agreement at any time during the
Supply Term upon at least thirty (30) months’ prior written notice to SPINCO. AstraZeneca will not provide written notice of termination prior to the first anniversary of the Effective Date. 

 

	 	(e)	 Termination following a Force Majeure Event. SPINCO may terminate this Supply Agreement on prior written
notice to AstraZeneca, within thirty (30) days of being provided with the Remediation Plan if implementation of the Remediation Plan (as amended to include SPINCO’s comments) will not enable AstraZeneca to resume delivery of the Supplied
Product to SPINCO in accordance with the Clinical Supply Plan within twelve (12) months of the commencement of the Force Majeure event. 

  

	20.	 EFFECT OF TERMINATION 

 

	20.1.	 Effect of Termination. Expiry or termination of this Supply Agreement for any reason shall be
without prejudice to either Party’s other rights and remedies or to any accrued rights and liabilities as the date of such expiry or termination. Without limitation of the foregoing, upon the expiration or earlier termination of this Supply
Agreement, (a) all unfilled Purchase 

  
 28 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
Orders shall be cancelled, and (b) SPINCO promptly shall pay to AstraZeneca (i) all amounts outstanding and remaining to be paid for Supplied Product delivered prior to the expiration
or termination; (ii) the costs of AstraZeneca’s then existing inventory of Materials that cannot otherwise be used in the business of AstraZeneca or its Affiliates without additional cost (provided that SPINCO shall not be obligated to
reimburse AstraZeneca for such costs to the extent this Supply Agreement has been terminated by SPINCO pursuant to Clause 19.2(b) due to breach by AstraZeneca); and (iii) the applicable Supply Price for all work in process and Supplied Product
Manufactured, but not then delivered, by AstraZeneca in accordance with and reliance on the Clinical Supply Plan. Additionally, AstraZeneca will deliver all such then existing inventory of Materials, all Special Equipment, and comply with the
Technology Transfer requirements of Clause 20.2. 

  

	20.2.	 Technology Transfer. In the event either Party gives notice not to renew this Supply Agreement in
accordance with Clause 19.1, or on earlier termination of this Supply Agreement pursuant to Clause 19.2 except where SPINCO is the Breaching Party, at SPINCO’s request, AstraZeneca and SPINCO shall cooperate in good faith to agree upon the
terms and conditions of a written technology transfer plan pursuant to which AstraZeneca and SPINCO shall use reasonable efforts to carry out a reasonable technology transfer to a mutually agreed Third Party contract manufacturer (the
“Technology Recipient”) of the process for manufacturing the Product but for clarity not information relating to [***], together with rights to acquire such proprietary media and feeds from an authorized Third Party, as and solely
to the extent necessary to enable the Technology Recipient to Manufacture the Product (such transfer, the “Technology Transfer”); provided that AstraZeneca shall not be required to transfer any MedImmune Manufacturing Technology
(and SPINCO shall not make or authorize any further transfer) unless the conditions set forth in this Clause 20.2 are satisfied to AstraZeneca’s reasonable satisfaction. 

 

	 	(a)	 Any Technology Transfer (or further transfer) shall be subject to (i) AstraZeneca, SPINCO and the
Technology Recipient agreeing upon reasonable terms and conditions to ensure the protection of and the proper use of any MedImmune Manufacturing Technology, (ii) the terms and conditions of any license or other agreement between AstraZeneca or
any of its Affiliates or AZ Suppliers and any Third Parties pursuant to which AstraZeneca, directly or indirectly, controls any MedImmune Manufacturing Technology or which otherwise encumber any rights of AstraZeneca or its Affiliates or AZ
Suppliers with respect thereto, and (iii) appropriate grant-back licenses to AstraZeneca with respect to any improvements, modifications, and enhancements in or to the MedImmune Manufacturing Technology. 

 

	 	(b)	 AstraZeneca has no obligation to disclose or transfer to any Technology Recipient any MedImmune Manufacturing
Technology that incorporates or may incorporate AstraZeneca’s or its Affiliates’ proprietary data, information or know-how or any MedImmune Manufacturing Technology that is not specifically
identified and agreed to in the technology transfer plan as being included in the Technology Transfer. 

  

	 	(c)	 The Technology Recipient shall be reasonably acceptable to AstraZeneca, and in no event shall AstraZeneca be
required to transfer the MedImmune Manufacturing Technology to more than one (1) Technology Recipient. 

  

	 	(d)	 [***] 

  
 29 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	20.3.	 Wind-down Period. In the event of termination of this Supply Agreement other than a termination
by AstraZeneca pursuant to Clause 19.2(b) or Clause 19.2(c), SPINCO shall have the option to require AstraZeneca to supply Supplied Products on the terms and conditions of this Supply Agreement until SPINCO is able to establish an alternate source
of Supplied Products; provided such period shall not exceed [***] from the effective date of termination. 

  

	20.4.	 Survival. Any provision of this Supply Agreement which expressly or by implication is intended to
come into or continue in force on termination or expiry of this Supply Agreement, including [***] shall remain in full force and effect. 

  

	21.	 INDEPENDENT CONTRACTORS 

 

	21.1.	 Independent Contractors. AstraZeneca is acting as an independent contractor under this Supply
Agreement. Nothing in this Supply Agreement or any circumstances associated with it or its performance give rise to any relationship of agency, partnership or employer and employee between SPINCO and (i) AstraZeneca, (ii) AstraZeneca’s
Affiliates and (iii) AstraZeneca’s and its Affiliates’ respective Personnel directly and effectively involved, if any, in the performance of this Supply Agreement, nor authorize either Party to make or enter into any commitments for
or on behalf of the other Party. 

  

	22.	 NOTICES 

  

	22.1.	 Notice Requirements. Subject to Clause 22.2, all notices and communications relating to this
Supply Agreement shall be in writing and delivered by hand or sent by post or email to the Party concerned at the relevant address set out in this Clause 22 below (or such other address as may be notified from time to time in accordance with this
Clause by the relevant Party to the other Party). Any communication shall take effect: 

  

	 	(a)	 if hand delivered, upon being handed personally to the addressee (or, where the addressee is a corporation, any
one of its directors or its secretary) or being left in a letter box or other appropriate place for the receipt of letters at the relevant Party’s address as set out below; 

 

	 	(b)	 if sent by first class registered post, at 10 a.m. on the second (2nd) business day after posting or if
overseas by international recorded post, at 10 a.m. on the fifth (5th) business day after posting; 

  

	 	(c)	 if sent by internationally recognized courier service which provides for overnight delivery, at 10 a.m. on the
second (2nd) business day after such communication was provided to the courier for delivery; and 

  

	 	(d)	 if sent by email, (i) when the email is sent to the correct email address; or (ii) the recipient of
the email has sent a reply. 

 For notices to AstraZeneca: 

AstraZeneca UK Limited 
 1 Francis
Crick Avenue 
 Cambridge Biomedical Campus 

  
 30 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 Cambridge 

CB2 0AA 
 Attn: Deputy General
Counsel, Corporate 
 with a copy to: 

[***] 
 For notices to SPINCO:

 Viela Bio, Inc. 
 1
Medimmune Way 
 Gaithersburg, MD 20878 

United States of America 

Attention: Bing Yao 
 with a
copy to: 
 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 

701 Pennsylvania Ave., NW, Suite 900 

Washington, DC 20004 
 United
States of America 
 Attention: Christopher Jeffers 

This Clause 22, however, shall not apply to the service of any proceedings or documents in any legal action, arbitration or any other form of
dispute resolution procedure. 
  

	22.2.	 Day-to-day
Communications. Day-to-day communications relating to the operation of this Supply Agreement, including Purchase Orders, shall be in writing (including email) to the
Account Managers or to such other persons as the Account Managers may agree and shall be deemed to be delivered when the email or facsimile is sent or if outside normal business hours in the country where the recipient is generally located, the
following working day in such country. 

  

	23.	 MISCELLANEOUS 

 

	23.1.	 No Set-Off. Except with respect to an obligation owed by
AstraZeneca under this Supply Agreement that has been finally adjudicated, settled or otherwise agreed upon by the Parties in writing, SPINCO shall not have any right of set-off (howsoever arising) in respect
of any sums payable in connection with this Supply Agreement and all sums payable by SPINCO to AstraZeneca under this Supply Agreement shall be paid in full without set-off, counterclaim or other deduction.

  

	23.2.	 Variation and Waiver. 

 

	 	(a)	 Amendments and additions to this Supply Agreement shall be valid only if made in writing by an authorized
signatory of both Parties unless a stricter form is prescribed by Applicable Laws. 

  

	 	(b)	 A waiver of any right or remedy under this Supply Agreement or by law is only effective if it is given in
writing and is signed by the person waiving such right or remedy. Any such waiver shall apply only to the circumstances for which it is given and shall not be deemed a waiver of any subsequent breach or default. 

  
 31 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(c)	 A failure or delay by any person to exercise any right or remedy provided under this Supply Agreement or by law
shall not constitute a waiver of that or any other right or remedy, nor shall it prevent or restrict any further exercise of that or any other right or remedy. 

 

	 	(d)	 No single or partial exercise of any right or remedy provided under this Supply Agreement or by law shall
prevent or restrict the further exercise of that or any other right or remedy. 

  

	23.3.	 Counterparts. 

 

	 	(a)	 This Supply Agreement may be executed in any number of counterparts, and by the Parties on separate
counterparts, but shall not be effective until each Party has executed at least one (1) counterpart. Each counterpart shall constitute an original of this Supply Agreement, but all the counterparts shall together constitute the one agreement.

  

	 	(b)	 Delivery of a copy of this Supply Agreement together with an executed signature page of a counterpart in AdobeTM Portable Document Format (PDF) sent by electronic mail shall take effect (subject to Clause 23.13) as delivery of an executed counterpart of this Supply Agreement. If this method is adopted,
without prejudice to the validity of this Supply Agreement, each Party shall provide the other with a hard copy original of that executed counterpart as soon as reasonably practicable thereafter. 

 

	23.4.	 Invalidity. Each provision of this Supply Agreement is severable and distinct from the others.
The Parties intend that each of those provisions shall be and remain valid and enforceable to the fullest extent permitted by Applicable Laws. If all or any part of any such provision is held to be or at any time becomes to any extent invalid,
illegal or unenforceable for any reason under any enactment or rule of law, it shall to that extent be deemed not to form part of this Supply Agreement but (except to that extent in the case of that provision) it and all other provisions of this
Supply Agreement shall continue in full force and effect and their validity, legality and enforceability shall not be affected or impaired as a result, subject to the operation of this Clause 23.4 not negating the commercial intent and purpose of
the Parties under this Supply Agreement. 

  

	23.5.	 Headings. The headings used in this Supply Agreement have been inserted for convenience of
reference only and do not define or limit the provisions hereof. 

  

	23.6.	 Assignment. No Party may assign or transfer this Supply Agreement or any rights or obligations
hereunder, directly or indirectly (by operation of Law or otherwise), without the prior written approval of the other Party and any attempted assignment without such required approval shall be null, void and of no effect; provided, however, that
(a) AstraZeneca may assign or delegate any or all of its rights, interests or obligations hereunder to an Affiliate of AstraZeneca or to any successor in interest (whether by merger, acquisition, asset purchase or otherwise) to all or
substantially all of the business to which this Supply Agreement relates, and may delegate any or all of its obligations hereunder to subcontractors, in each case, without SPINCO’s prior written approval, and (b) SPINCO may assign its
rights, interests, and obligations hereunder (in whole and not in part) to a wholly owned Affiliate of SPINCO without AstraZeneca’s prior written approval. In addition, following the earlier to occur of (c) the consummation in full of the
Milestone Closing (as defined in the Securities Purchase Agreement), and (d) the consummation of a Qualified IPO (as defined in the Restated 

  
 32 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	
Certificate (as defined in the Securities Purchase Agreement)), SPINCO may assign its applicable rights, interests, and obligations hereunder related to the Product to a Third Party without
AstraZeneca’s prior written approval, so long as (i) such assignment shall be in connection with the divestment by SPINCO of all or substantially all of the assets relating to the Product (whether by asset purchase or exclusive out-license), (ii) in connection therewith, SPINCO also assigns to such Third Party its applicable rights, interests, and obligations under the other Transaction Agreements related to the Product, and
(iii) proper provision shall be made so that the successors and assigns of SPINCO shall succeed to SPINCO’s applicable rights and obligations set forth herein and therein. Furthermore, if SPINCO or any of its successors or assigns
(e) consolidates with or merges into any other Person and shall not be the continuing or surviving corporation or entity of such consolidation or merger or (f) transfers, licenses or conveys all or substantially all of its rights and
assets to any Person, then, and in each such case, SPINCO may assign its rights, interests and obligations hereunder (in whole and not in part) to such Person without the prior written approval of AstraZeneca so long as in connection therewith
SPINCO (i) also assigns to such Person all of its applicable rights, interests, and obligations under the other Transaction Agreements, and (ii) ensures that proper provision shall be made so that the successors and assigns of SPINCO shall
succeed to SPINCO’s rights and obligations set forth in this Supply Agreement. Notwithstanding anything to the contrary set forth herein, no assignment or succession pursuant to this Clause 23.6 shall relieve the assigning Party or predecessor
Party of its obligations hereunder. Upon any permitted assignment, the references in this Supply Agreement to a Party shall also apply to any such assignee unless the context otherwise requires. Notwithstanding the foregoing, in the event a Party
assigns its rights or obligations under this Supply Agreement or otherwise makes payments from a jurisdiction other than the jurisdiction in which such Party is organized (each, an “Assignment”), and immediately after such
Assignment the amount of Tax required to be withheld on any payment pursuant to this Supply Agreement is greater than the amount of such Tax that would have been required to have been withheld absent such Assignment, then such increased withholding
tax shall be borne by the Party making such Assignment. 

  

	23.7.	 Subcontracting. 

 

	 	(a)	 AstraZeneca shall have the right to subcontract, in whole or in part, the Manufacturing and supply of the
Supplied Products and the performances of the Services. 

  

	 	(b)	 Each Party remains responsible for the acts or omissions of its Affiliates or Third Parties to whom it
subcontracts or delegates any of its obligations, as if they were its own. 

  

	23.8.	 No License. Nothing in this Supply Agreement shall be deemed to constitute the grant of any
license or other right in either Party to or in respect of any product, patent, trademark, Confidential Information, trade secret or other data or any other intellectual property of the other Party except as expressly set forth herein (including in
Clause 13.7(b)). 

  

	23.9.	 No Rights of Third Parties. 

 

	 	(a)	 An Affiliate of AstraZeneca, acting with the written consent of AstraZeneca, shall be entitled to enforce those
provisions of this Supply Agreement expressed to confer any right or benefit thereon. 

  

	 	(b)	 Except as provided in Clause 23.9(a) and except for any assignment under Clause 23.6, none of the provisions of
this Supply Agreement shall be for the benefit of or enforceable by any Third Party, including any creditor of either Party hereto. No such Third Party shall obtain any right under any provision of this Supply Agreement or shall by reasons of any
such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either Party hereto. 

  
 33 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	23.10.	 Joint Drafting. The Parties have participated jointly in the negotiation and drafting of this
Supply Agreement. In the event an ambiguity or question of intent or interpretation arises, this Supply Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring
either Party by virtue of the authorship of any of the provisions of this Supply Agreement. 

  

	23.11.	 Entire Agreement. This Supply Agreement, and any agreement or document referred to in it,
contains the entire agreement between the Parties with respect to the subject matter of this Supply Agreement, and supersedes all previous agreements and understandings between the Parties with respect to that subject matter. Each Party acknowledges
that, in entering into this Supply Agreement and the agreements and documents referred to in it, it does not rely on any statement, representation, assurance or warranty (whether it was made negligently or innocently) of any person (whether a Party
to this Supply Agreement or not) which is not expressly set out in this Supply Agreement or those documents (a “Representation”), and that it shall have no cause of action against the other Party arising out of any Representation
except in respect of any fraudulent misrepresentation by the other Party. Each Party acknowledges that its only right and remedy in relation to any representation, warranty or undertaking made or given in connection with this Supply Agreement shall
be for breach of the terms and conditions of this Supply Agreement and each Party hereby waives all other rights and remedies (including those in tort or arising under statute) in relation to any such representation, warranty or undertaking.

  

	23.12.	 Governing Law, Jurisdiction and Dispute Resolution. 

 

	 	(a)	 This Supply Agreement shall be governed by and construed in accordance with the Laws of the State of New York,
excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Supply Agreement to the substantive law of another jurisdiction. 

 

	 	(b)	 The terms of this Clause 23.12(b) shall apply with respect to any dispute arising out of or relating to this
Supply Agreement other than disputes that may be determined by the Independent Expert under Clauses 10.5 and 10.6 or 11.3(c) or an Auditor under Clause 7.8. 

  

	 	(i)	 The Parties agree to unconditionally and irrevocably submit to the exclusive jurisdiction of the United States
District Court for the Southern District of New York sitting in New York County or, if such court does not have subject matter jurisdiction, then the Commercial Division, Civil Branch of the Supreme Court of the State of New York sitting in New York
County and any appellate court from any thereof, for the resolution of any such claim or dispute. 

  

	 	(ii)	 The Parties hereby irrevocably waive, to the fullest extent permitted by Applicable Law, any objection which
they may now or hereafter have to the laying of venue of any such dispute brought in such court or any defense of inconvenient forum for the maintenance of such dispute. Each of the Parties agrees that a judgment in any such dispute may be enforced
in other jurisdictions by suit on the judgment or in any other manner provided by Applicable Law. 

  
 34 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

	 	(iii)	 Each of the Parties hereby consents to process being served by any Party in any suit, action or proceeding by
delivery of a copy thereof in accordance with the provisions of Clause 22.1. 

  

	 	(c)	 The application of the Uniform Law on the International Sale of Goods and the Uniform Law in the Formation of
Contracts for the International Sale of Goods - both dated July 17th, 1973 - and of the UN agreement on the Sale of Goods dated April 11th, 1980 shall be excluded. 

 

	23.13.	 Delivery of Agreement. The Parties do not intend this Supply Agreement to be delivered by, or to
become legally binding on, any of them until the date of this Supply Agreement is written at its head, notwithstanding that one or more of them may have executed this Supply Agreement prior to that date being inserted. 

IN WITNESS WHEREOF, the Parties have caused this Supply Agreement to be executed in two counterparts
by their respective duly authorized representatives as of the date set forth at the beginning of this Supply Agreement. 

[Signature pages follow] 

  
 35 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 EXECUTION: 

SIGNED for and on behalf of  

AstraZeneca UK Limited  

Signature: [***] 
 [***] 

[***] 
 Authorized Signatory

  
 [Signature Page to
Clinical Supply Agreement] 
 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE
INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

			
	SIGNED for and on behalf of
	Viela Bio, Inc.

			
		
	Signature:	 	/s/ Zhengbin (Bing) Yao

			
		
	Name:	 	Zhengbin (Bing) Yao

			
		
	Title:	 	CEO
	
	Authorized Signatory

  
 [Signature Page to
Clinical Supply Agreement] 
 [*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE
INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 SCHEDULE 1 

One-Time Costs [***] 
  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

Ongoing Costs [***] 
  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

Regulatory Support (to be provided only after sponsorship of any IND for the Product has been transferred to SPINCO) 

 

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 

 EXHIBIT 1: 

Documentation to accompany deliveries 
  

	☐	 Invoice 

  

	☐	 Pack list 

  

	☐	 Certificate of Analysis (and where relevant, Certificate of Origin) 

 

	☐	 Or as otherwise specified in the Clinical Quality Agreement or as mutually agreed or required for specific
countries 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]